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1 Introduction 1
1 Introduction
In 1963, Berg first reported the identification of lipoprotein (a) [Lp(a)] in human
plasma as an antigen associated with low-density lipoprotein (LDL) [1]. He also
performed a family study and reported in the same year an autosomal genetic in-
heritance of the presence of Lp(a) [2]. Further investigation revealed that Lp(a) was
a macromolecule, comprised of LDL and a glycoprotein component [3]. In the 1970s
the first studies suggested an association of plasma Lp(a) levels with atherosclerotic
vascular disease [4, 5]. Though intense research on Lp(a) for decades, many aspects
on the function, regulation of plasma concentration and genetics of Lp(a) still have
to be revealed [6].
1.1 Structures of the Lp(a) particle
The Lp(a) particle is made up by a LDL particle and the glycoprotein component
apolipoprotein a [apo(a)] [3]. These two structures are linked covalently by a single
disulfide bond and are further stabilized by non-covalent interactions [3]. Figure 1.1
shows the structural composition of the Lp(a) particle.
1.1.1 The LDL component
Cholesteryl esters and triglycerides build up the lipid core of the LDL component [7].
The lipid core is surrounded by a monolayer of unesterified cholesterol, phospholipids
and, as the protein component, one apolipoprotein B-100 (apo B-100) per particle,
as shown in figure 1.1 [7]. The apo(a) component surrounds the particle and is
linked to the apoB-100 molecule [7].
1.1.2 The apo(a) component
The apo(a) protein component, encoded by the gene LPA, has a remarkable structure
[8]. Several cysteine residues lead to the formation of intramolecular disulfide bonds
that give the molecule the look of nodules in the display of the two-dimensional
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Figure 1.1: Structural composition of the Lp(a) particle, as described in the text. Figure from
[7].
amino acid chain [9]. These nodules, better known as kringles, are the structural
specialty of apo(a). Apo(a) has a strong homology to plasminogen, a proenzyme
of the fibrinolytic system [10]. Apo(a) and plasminogen contain both a series of
motifs called kringles [10]. The plasminogen gene contains coding sequences for 5
different kringle domains, kringle I to kringle V [11]. The kringle structures of apo(a)
resemble some of the kringle structures of plasminogen, and are therefore divided
into kringle IV- like and kringle V-like [12]. Figure 1.2 displays one of the kringles
of apo(a).
Figure 1.2: Amino acids of a kringle structure, organized into three loops by
disulfide bonds between the cysteine residues (C), modified after
[13].
Each kringle contains about 77 to 79 amino acids, the kringles are connected by
linker regions of 26 to 36 amino acids [14, 10]. The kringles are each coded by two
separate exons with introns inserted at homologous positions as in the plasminogen
gene (in the middle and at both ends of each kringle) [15]. The number of KIV-2
repeats is encoded by corresponding numbers of 5.5 kb DNA units, each consisting
of two exons (of 342 bp length in total), separated by a 4 kb intron [14]. The KIV-2
structures are separated by 1.2 kb introns [14].
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Each apo(a) molecule contains only one kringle V-like structure, but several vari-
ants of kringle IV-like [16, 14], as depicted in figure 1.3.
Figure 1.3: Apolipoprotein (a) is made of 10 different types of kringle IV (KIV), followed by a
kringle V (KV) and a nonfunctional protease domain (P). Kringle IV type 2 (KIV-2)
is variable in its repeat number (indicated by n). Modified after [17].
One of these kringle IV-like stuctures, kringle IV type 2 (KIV-2) can be present in
several repeats [16, 14]. The number of KIV-2 repeats is highly variable, 3 to more
than 40 copies have been found, therefore the molecular mass of apo(a) is highly
polymorphic, with a range between 300 and 800 kDa [16, 14]. The other kringle IV
like domains (KIV-1 and KIV-3 to KIV-10) are present in single copy [18, 16, 14].
Apo(a) is a glycoprotein, and sites for N-linked glycosylation are present within
the core of each KIV motif, whereas a minimum of six O-linked glycosylation sites
are present within the linker sequences that join individual kringles [10, 19, 20]. The
hydrophilic O-linked glycans are mainly composed of monosialylated core structures
[21]. Apo(a) and thus, Lp(a), is heterogeneous in its glycosylation, but the influence
on the in vivo properties is still unclear [22].
1.2 Structure-function relationships in Lp(a)
components
Epidemiological studies identified elevated serum Lp(a) concentrations as an inde-
pendent risk factor for coronary heart disease (CHD) (see section 1.5). The high
degree of homology between apo(a) and plasminogen has evoked speculations about
a role of Lp(a) in thrombosis, while the LDL-like component of Lp(a) proposed
a possible role in atherosclerosis [10]. Several relationships between structure and
function of apo(a) have been investigated, and specific functions have been mapped
to discrete structural units in apo(a).
According to a concept based on homology between apo(a) and plasminogen,
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Lp(a) would interfere with the process of plasmin generation and, in consequence,
lead to decreased fibrinolysis and increased accumulation of fibrin in the atheroscle-
rotic plaque.
But, unlike plasminogen, the protease-like domain of apo(a) can not be activated
by tissue plasminogen activator, urokinase or streptokinase and is catalytically inac-
tive [23, 24]. Therefore, it has been speculated that Lp(a) might act as a competitive
inhibitor for plasminogen activation and inhibit plasmin-mediated thrombus degra-
dation by binding to fibrin. The first investigations about Lp(a) aimed at this
possible role in thrombogenesis and showed interference with several steps of the
fibrinolytic pathway [23, 25].
The different kinds of kringle IV-like structures have been investigated and differ-
ent functions have been revealed mostly by in vitro experiments [26, 27].
KIV-2, as already mentioned, is responsible for the isoform size heterogeneity
and the number of the LPA KIV-2 repeats determines about 50% of the variability
of Lp(a) levels with an inverse correlation between number of KIV-2 repeats and
Lp(a) levels [28, 29, 30]. One explanation for this inverse correlation was reduced
secretion efficiency of larger apo(a) isoforms, leading to their increased intracellular
degradation [31]. Other investigations have shown that the number of KIV-2 has
an influence on the conformational status of the apo(a) component, and therefore
influences the efficiency of covalent Lp(a) assembly [32, 33]. It has been shown that
shorter apo(a) isoforms tend to stay in a open conformation, which favors efficient
Lp(a) assembly, whereas in longer, more flexible, apo(a) isoforms intramolecular
interaction can lead to a closed conformation that hinders efficient Lp(a) assembly
[32].
Lp(a) is cleaved in vivo between the KIV-4 and the KIV-5 domain by elastases,
dividing apo(a) in two parts, with the C-terminal domain spanning from KIV-5
to the protease domain [26]. Recent studies in transgenic mice indicate that this
C-terminal apo(a) component mediates Lp(a) clearance from plasma by the liver
[34].
The domains KIV-5 to KIV-8 have weak lysine binding sites, whereas KIV-10
has a strong lysine binding site [27]. These lysine binding sites have been shown to
mediate the non-covalent step of Lp(a) assembly [35].
The part from KIV-5 to the protease domain at the C-terminus, might contribute
to the preferential retention of Lp(a) in atherosclerotic lesions. Binding to laminin
and other components of the extracellular matrix has been shown for these parts of
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apo(a) [36, 37].
KIV-6 and KIV-7 are the domains that are recognized by the foam cell receptor,
and Lp(a) may participate in macrophage foam cell formation [38].
In the KIV-9 domain, an unpaired cysteine residue mediates the formation of the
single disulfide bond between the apo(a) and the apoB-100 component of LDL [39].
Therefore, KIV-9 domain is essential for the formation of stable Lp(a) particles [40].
The formation of a Lp(a) particle is a two step process; initial non-covalent in-
teractions between apo(a) and apoB-100 precede the formation of a disulfide bond
[41]. It has been shown that the conformation of the apo(a) molecule is important
for efficient assembly of the Lp(a) particle [32, 33]. A closed as well as an open
conformation status of apo(a) have been identified, and can in vitro be changed by
lysine analogues [9]. Furthermore the apo(a) molecule has one KV like domain, as
already mentioned, and a protease domain.
Edelstein et al. found that lysine residues of the KV domain of apo(a) mediate
binding with oxidized phosphatidylcholine and postulated that apo(a) might act as
a scavenger and prevent LDL from oxidation [13].
Recent findings by Tsimikas et al. showed that Lp(a) levels strongly correlate
with the oxidized phospholipid/apoB-100 ratio in plasma and that both factors are
associated with the extend of angiographically documented coronary artery disease
[42]. In conjunction with the finding that the oxidized phospholipids are physically
associated with Lp(a) via the KV domain of apo(a) [13], this supports the idea that
in a setting of enhanced oxidative stress the atherogenic properties of Lp(a) might
be enhanced through pro-inflammatory oxidized phospholipids.
1.3 Function of Lp(a)
The physiological role of the complex macromolecule Lp(a) in the organism is still
unknown. Individuals with near absence of Lp(a) in plasma have been identified and
characterized, but no deficiency syndrome or any kind of disease was found [40]. A
pathophysiological role of elevated Lp(a) levels in the context of atherosclerotic and
cardiovascular disease seems quite clear and many possible pathological functions of
Lp(a) have been proposed, as mentioned above. However, a concrete pathological
mechanism in human disease has not yet been shown.
1 Introduction 6
1.4 Evolution of Lp(a)
Apo(a) protein (and the Lp(a) particle) has been detected in several species of
nonhuman primates and Old World monkeys (as chimpanzee, orangutan, gorilla,
rhesus monkey and baboon), although most mammals lack apo(a) [43, 44, 45, 46].
In most of these species it has been shown that the protein is polymorphic [45].
Apo(a) belongs to an extended gene superfamily that contains domains that re-
semble the serine protease trypsin [47]. One branch of the family tree that contains
only kringle and protease-like domains includes plasminogen, apo(a) and hepatocyte
growth factor [47]. LPA evolved from a duplicated plasminogen gene during recent
primate evolution [10].
The LPA gene is located on human chromosome 6q26-27 in close proximity to the
plasminogen gene from which it evolved during primate evolution by duplication,
deletions, gene conversions and mutations [10, 48, 43].
Furthermore Lp(a) is also found in the European hedgehog. However, the hedge-
hog version of apo(a) appears to have evolved separately from the human version,
as it shows strong differences in composition to primate apo(a) [44]. The hedgehog
apo(a) lacks sequences that resemble the K-IV, K-V and protease domain, but in-
stead is composed of tandem repeats of sequences homolog to the K-III domain of
plasminogen [44].
Kraft et al. suggested that Lp(a) is an old African trait, as they found the
highest Lp(a) concentrations in Khoi San from southern Africa, one of the oldest
living populations [49]. The distribution of Lp(a) levels in different ethnic groups
(Khoi San, South African Blacks, Hong Kong Chinese and Caucasians) was found
to be heterogeneous, with a broad distribution in Africans and a highly skewed
distribution (towards lower levels) in Caucasians [49].
1.5 Elevated Lp(a) levels as a cardiovascular risk
factor
Several studies on Lp(a) and its role in cardiovascular disease have been performed.
The majority of studies performed on the on the impact of elevated Lp(a) levels on
the development of cardiovascular disease provided evidence for Lp(a) as a indepen-
dent predictor of myocardial infarction (MI) [50, 51, 52], coronary artery disease
(CAD) [53, 54, 55], and extent of the disease process [56, 57, 58, 59]. Some stud-
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ies have shown weak [60] or no association with various cardiovascular phenotypes
[61, 62, 63, 64, 65, 66]. A meta-analysis of 27 prospective studies has shown a clear
association between Lp(a) and CHD including information from 5,436 CHD cases
that were observed during a mean follow-up time of 10 years [55]. Risk of CHD was
at 70% increased in people from the general population with Lp(a) levels in the top
third of baseline measurement compared to those in the bottom third [55]. Other
studies showed that high Lp(a) levels potentiate the risk rising from high LDL, it has
therefore been discussed controversly, weather Lp(a) is a independent risk factor for
CHD [67, 68, 69, 57]. However, from the insights in structure-function relationships
of Lp(a) is has become clear that a complex macromolecule as Lp(a) can have a
influence in multiple stages of the atherosclerotic process through several different
mechanisms.
The progress of atherosclerosis can finally lead to the complication of myocardial
infarction, one of the most common causes of death in Western societies [70].
Epidemiologic studies have identified risk factors for the development of atheroscle-
rosis [70]. Elevated levels of LDL, low levels of HDL, hypertension, diabetes mellitus,
male gender, elevated levels of homocysteine, metabolic syndrome, insulin resistance,
obesity and family history of cardiovascular disease have been identified apart from
elevated Lp(a) levels as factors contributing to the development of atherosclerosis
[70]. Also environmental factors as smoking, lack of exercise and high fat diet can
promote atherosclerosis [70].
While many risk factors for atherosclerosis can be influenced by medication (for
example hypertension or high LDL cholesterol) or changes in lifestyle (smoking,
obesity), no applicable therapy is available for elevated Lp(a) levels [70, 22].
1.6 Metabolism of Lp(a)
Lp(a) levels may vary 1000-fold between individuals, but they exhibit a high degree
of stability within persons [71]. Correlation between two measurements taken some
years apart in the same individual is 0.9 (self-correlation) [72]. This high inter-
individual variability is largely determined by the LPA gene on chromosome 6q27
and several polymorphisms of LPA have been shown to influence the size and amount
of apo(a), as well as Lp(a) plasma levels [8, 6, 73, 28, 29].
It has been shown that the subunits of Lp(a), apo(a) and apoB-100 containing
lipoproteins are independently processed and secreted by liver cells [74, 75, 76]. It
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is suggested that the Lp(a) particle forms in the extracellular compartment. Very
recently, a study has provided evidence that the disulfide bond formation between
apo(a) and apoB-100 can be markedly enhanced by a putative Lp(a) oxidase activity
secreted by a human liver cell line [77]. The identification of a putative, extracellular
Lp(a) oxidase could provide a new modulator of Lp(a) levels.
Lp(a) concentrations have been found to be determined at the level of synthesis
rather than catabolism [78].
The pathway of Lp(a) catabolism in vivo remains unclear, and no major site of
catabolism of Lp(a) particles has been identified in humans [22]. Experiments in
transgenic mice indicate that Lp(a) is cleared from the plasma primarily by the liver
in a process mediated by apo(a) [34]. This apo(a) clearance in transgenic mice has
been shown to be independent from LDL receptor, apoE or the asialoglycoprotein
receptor and is supposed to run via a receptor that is responsible for the hepatic
clearance of cholesterol-rich remnant lipoproteins (RLP) [34, 79].
Lp(a) concentrations are relatively resistant to alteration by traditional pharma-
cologic and non-pharmacologic approaches [22]. In contrast to plasma LDL con-
centrations, Lp(a) concentrations are thought to be relatively resistent to diet or
exercise [22]. Few drugs have been reported to be capable of reducing Lp(a) concen-
trations in vivo, as niacin in high doses, aspirin and others [80, 22]. For the influence
of statin therapy an Lp(a) concentrations, results are unclear, a modest reduction as
well as a modest increase of Lp(a) concentrations were reported for different statins
[22]. The most efficient method to decrease Lp(a) concentrations is LDL or Lp(a)
apheresis. This costly procedures can decrease Lp(a) concentrations by 50% [22].
1.7 Heritability of Lp(a) levels
In fact, the variation of the Lp(a) plasma levels is under strong genetic influence
with a heritability of >90% [81, 82]. Twin, family and sib-pair linkage studies have
revealed that the intra-individual variability in plasma concentration is under strong
genetic control and almost entirely explained by variations at the LPA gene locus
[83].
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1.8 Genetic polymorphisms of the LPA gene
Several genetic polymorphisms of the LPA gene have been described, including single
nucleotide polymorphisms and different kind of repeat polymorphisms.
1.8.1 Repeat polymorphisms
As explained above, the most prominent polymorphism of the protein is the variable
number of KIV-2 repeats. An other repeat polymorphism is located in the promotor
region of gene.
Variable number of KIV-2 repeats
The number of the LPA KIV-2 repeats appears to determine about 50% of the vari-
ability of Lp(a) levels and the number of KIV-2 repeats are negatively correlated
with Lp(a) levels [28, 29, 30]. Though the number of KIV-2 repeats has a strong
influence on Lp(a) levels in most populations, the variance in Lp(a) levels between
individuals with alleles for same number of KIV-2 repeats still differs by a factor of
200 [49, 84]. The heterozygosity for the apo(a) KIV-2 alleles is high, approximately
94% in Caucasians [49]. Most studies investigating the relation between the num-
ber of KIV-2 repeats and Lp(a) levels, used the method of apo(a) phenotyping by
immunoblotting of serum, therefore providing information about the number of ex-
pressed KIV-2 repeats. Some studies have also investigated in parallel the number of
repeats on gene level, and revealed that so called “null” -alleles exist [85]. These not
expressed apo(a) alleles were found to be distributed over the whole range of KIV-2
repeat number in different populations [49]. In Caucasians, the relative frequency of
non-expressed alleles increased with KIV-2 repeat number [49]. “Null” -alleles were
found to be more frequent in Caucasians (18.9%) than in other populations [49].
Variable number of pentanucleotide repeats
A repeat polymorphism of the pentanucleotide sequence TTTTA was found at -1371
upstream of the apo(a) translational start site of LPA [47]. This pentanucleotide
repeat (PNR) polymorphism in the promotor region may account for 3-14 % of the
inter-individual variations in plasma concentrations in Caucasians [50, 29]. The PNR
polymorphism, usually varies from 8 to 11 repeats, depending on the population and
has been associated with Lp(a) levels repeatedly in different populations [56, 29, 86,
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87, 88]. Lower numbers of PNR repeats have been associated with higher Lp(a)
levels in Caucasians [50].
1.8.2 Single nucleotide polymorphisms
Other polymorphisms of the LPA gene have been identified and revealed small effects
on Lp(a) plasma concentrations, however, in total, they do not fully explain the
genetic variation of Lp(a) levels [87, 89, 90, 91].
SNP markers in the 5-prime region
Several SNPs in the 5-prime flanking region of the LPA gene have been investigated:
Brazier et al. investigated three SNPs (-914 G/A, -49 C/T and -21 G/A) in the
promotor region of the gene and their association with Lp(a) levels and MI in a
French and Irish population [50]. They genotyped 594 MI patients, and 683 controls,
and found no association of the SNPs with MI or Lp(a) levels, but revealed a strong
LD between these SNP markers and the PNR polymorphism [50].
Ichinose et al. identified three polymorphisms in the LPA 5-prime flanking region:
-772 A/G, +93 C/T and +121 G/A, relative to the transcription start site [92].
Suzuki et al. investigated the influence of these three SNPs on gene expression
[87]. Deletion analysis in an in vitro experiment revealed that a T allele at position
+93 led to negative regulation in gene expression and the A allele at position +121
led to positive regulation of gene expression [87]. They also measured Lp(a) levels
in Japanese individuals and found significantly higher Lp(a) level in homozygous
carriers of the +93 C allele and the +121 A allele, compared with homozygous
carriers of the +93 T allele and the +121 G allele [87].
Kraft et al. showed that the +93 C/T polymorphism has no impact no Lp(a)
concentrations in Caucasians, as this SNP is in strong linkage disequilibrium with
the PNR polymorphism [89].
For Caucasian populations, the SNPs in the 5-prime flanking region of LPA, have
been shown to be in linkage disequilibrium (LD) with the PNR [50]. In summary, for
none of the SNP markers in the 5-prime region an independent influence on Lp(a)
levels could be shown in Caucasian populations [50].
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SNP markers in exon regions
The other SNP markers that have been investigated so far are mainly located in exon
regions of the LPA gene. Ogorelkova et al. identified 14 exon SNPs in apo(a) KIV-
6, KIV-8, KIV-9, and KIV-10, but found no sequence variants common to Africans
and Caucasians, when they investigated healthy individuals [91]. A substitution in
KIV-6 and another in KIV-8 were associated with Lp(a) levels significantly below
average in Africans [91]. In contrast, a substitution in KIV-9, which occurred with
a frequency of 8% in Khoi San Africans, resulted in a significantly increased Lp(a)
concentration [91]. For the SNPs that were found only in Caucasians, no association
with Lp(a) levels could be detected, as the SNPs were to rare for statistical analysis
[91].
Recently, Luke et al. investigated a population of Americans with European
descent and reported an association between Lp(a) levels as well as CAD and an
exonic SNP, rs3798220, located in the protease domain of LPA [93]. This is the first
described SNP marker of LPA significantly associated with MI, independent from
Lp(a) levels [93].
SNP markers and not expressed apo(a) isoforms
Two SNPs have been reported to be associated with not expressed apo(a) isoforms,
also named “null”-alleles.
Ogorelkova et al. described a G to A substitution at the +1 donor splice site
of the apo(a) KIV-8 intron that results in alternative splicing of the intron and
thus encodes a truncated apo(a) form [40]. This SNP marker was identified in a
Caucasian sample (n=239) with an allele frequency of 6% [40].
Parson et al. described a C/T SNP at nucleotide 61 in exon 1 of the KIV-2
domain, with this nonsense mutation producing a stop codon (R21X) the resulting
protein is predicted to be truncated [90]. An allele frequency of 0.02 was detected
for this SNP [90].
These described SNP markers are rare and, therefore, account only for a small
proportion of number of not expressed apo(a) isoforms.
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1.9 Aim of this investigation
In this investigation different methods were used to explore the influence of addi-
tional SNP markers located in the LPA gene region on the Lp(a) levels and risk for
myocardial infarction. With a pooling approach using information from a previous
linkage analysis, relevant SNP markers should be identified. Replication of these
relevant SNP markers in a large sample with a different technique and a detailed
analysis of the association should confirm the findings. The replication of findings
in different population samples should provide further evidence for a robust finding,
and allow a more generalized statement.
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2 Materials and methods
Phenotypic differences between individuals of a species are mostly caused by genetic
variants [94]. In the human genome, millions of polymorphisms have been identi-
fied so far, the vast majority are changes of a single nucleotide, known as single
nucleotide polymorphism (SNPs) [94]. The Human Genome Project enhanced the
identification of DNA variations, and different methods of typing DNA variations
(genotyping) were developed [94]. Two different PCR-based techniques for the pur-
pose of genotyping were performed in this work and data resulting from a third
technique were analyzed. The first technique of allele-specific PCR was used to an-
alyze the differences in allele frequency between two samples. The second technique
of TaqMan genotyping allowed the exact determination of genotypes for a large set
of individual samples. Through an additional technique, the Affymetrix GeneChip
Human Mapping 500K Array Set, a huge set of SNP markers for a large set of
individual samples was obtained.
2.1 DNA processing
2.1.1 Isolating genomic DNA from blood
DNA from all participants of the German MI Family Study was extracted from
EDTA blood samples (peripheral blood) in the laboratory at the University of Re-
gensburg. For this purpose, a commercially available PureGene Genomic DNA Pu-
rification Kit (Gentra System Inc. Minneapolis, USA) and the according standard
protocol was used. After photometric concentration and purity measurement, DNA
aliquots with a concentration of about 100 ng/µl were stored at -20°C in a tube
storage system (ABgene, Hamburg, Germany). After sample selection (see 2.2.2
and 2.3.2) the DNA tubes were identified in the ABgene tube storage system and
fitted into 96-well plate format for further processing.
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2.1.2 DNA preparation for pooled DNA samples
The aim of the allele-specific PCR on pooled DNA samples was to reveal differences
in allele frequencies between two samples. For pooling of DNA samples an exact
quantification of the single DNA samples is crucial, as differences in the DNA content
of the individual samples directly influence the amount of allele brought into the
sample pool.
DNA quantification and dilution
For every single DNA sample, a volume of 100 µl was removed from the ABgene tube
using the automated pipetting system TECAN Gemini Freedom 150 (Tecan, Crail-
sheim, Germany). This robot allows to retain DNA from the storage tubes without
opening the tubes. To ensure the quality of the DNA samples and to prevent con-
tamination of DNA samples a manual removal of DNA from the storage tubes is not
possible. The DNA samples were transferred into 96-well deep-well plates (Corning,
NY, USA). Then a 5 µl aliquot was pre-diluted with water (1:10), and from this
dilution, a 5 µl aliquot was used for DNA quantification with PicoGreen (Molecu-
lar Probes, Eugene, OR, USA), a DNA intercalating fluorescent dye. The resulting
DNA-dye-complex absorbs blue light (λmax = 485 nm) and emits green light (λmax
= 535 nm). In a 96-well black measurement plate (Nunc, Wiesbaden, Germany) the
5 µl DNA solution were diluted with 95 µl 1xTE buffer (10mM Tris, 1mM EDTA)
and mixed thoroughly. Per measurement plate a DNA standard dilution series with
8 different concentrations of λ DNA between 0 and 1 ng/µl (0; 0.001; 0.01; 0.125;
0.25; 0.5, and 1 ng/µl, respectively, each in duplicate) was used to create an 8 point
calibration curve. The PicoGreen stock solution was then diluted 1:200 with 1xTE
buffer, and 100 µl of this solution were added to each well of the measurement plate.
After 5 min incubation of the plate, fluorescence was measured in the Tecan Spec-
tra Fluor Plus (Tecan, Crailsheim, Germany) with a excitation wavelength of 485
nm and an emission wavelength of 535nm; the software Xfluor4 allows the quan-
tification of the DNA samples using the 8 point calibration curve of standardized
DNA. According to this measured DNA concentration, samples were then diluted
with 0.1xTE buffer (containing 1mM Tris and 0.1mM EDTA) to the concentration
of 8 ng/µl. The DNA concentration of these diluted samples was then confirmed
twice by photometrical measurement (Gene Quant Pro, Amersham (now GE Health
Care), Freiburg, Germany) without further dilution. In photometric concentration
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measurement the optical density (OD) of a DNA solution was measured at 260 nm.
An OD of 1 at 260 nm corresponds to a concentration of 50 ng/µl double-stranded
DNA [95]. DNA samples were then diluted to the exact concentration of 8.0 ng/µl,
and once again measured in the photometer. According to this measured concen-
tration a further dilution to 4 ng/µl was made in TE buffer. This 4 ng/µl DNA
solutions were used for pooling.
Pooling of DNA samples
Equal amounts of DNA samples (at 4 ng/µl) from 42 individuals contributing to the
linkage signal (see sample selection) were used to establish two pools, each pool con-
taining 21 individual samples. This procedure was replicated twice, resulting in two
“contributor” pools, each in triplicate. DNA from 42 individuals that were identified
as not contributing to the linkage signal was also joined in two “non-contributor”
pools (each as triplicate) of 21 individuals. 5 µl of each pool, corresponding to 20 ng
of DNA, was pipetted in 384-well plates and dried overnight before the application
of 15 µl of PCR master mix.
2.1.3 DNA preparation for individual genotyping
DNA quantification, dilution, normalization
DNA samples were transferred into 96-well plates using the automated TECAN
pipetting system and the Gemini 3.2 software (Tecan, Crailsheim, Germany). DNA
samples were 1:10 diluted with water. Out of this diluted plate a 5 µl aliquot was
removed for DNA quantification with PicoGreen assay (Molecular Probes, Eugene,
OR, USA) as described above. After the concentration measurement, worklists for
automated pipetting of normalized DNA masterplates (2 ng) were prepared using
Microsoft Excel macros delivered with the automated pipetting system. Pipetting
of the normalized plates was automated and performed with the Tecan pipetting
system and its DNA normalization software.
Pipetting of 384-well DNA microplates
Four 96-well plates (with 2 ng DNA / µl) were used to create one 384-well plate with
10 ng of DNA per well. Every 384-well plate contained the minimum of 4 empty
wells serving as no template controls in PCR. DNA was dried overnight at room
temperature and then stored at -20°C until usage.
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2.2 Allele-specific PCR on pooled DNA
The allele-specific PCR is an application of quantitative real-time PCR. When per-
formed on pooled DNA, the allele-frequencies of a SNP marker in the pool can be
determined [96].
2.2.1 Quantitative real-time PCR
Before starting a PCR reaction the sequence to be amplified (target sequence) must
be identified, and oligonucleotide primers that are complementary to DNA sequences
located on opposite DNA strands and flanking the target sequence must be designed.
PCR consists of cycles of denaturation, annealing of primers and DNA synthesis.
During the first step, the denaturation, the PCR mixture is heated to 90-95 °C
and the DNA double strands separate, as the inter-molecular hydrogen bonds are
disrupted. In the next step the PCR mixture is cooled to down to about 50-65 °C.
During this cooling process the short molecules of the oligonucleotide primers quickly
find their complementary DNA sequences flanking the target sequence and build a
short double strand with a free 3’ end (annealing). In the extension step (60-72°C),
heat stable DNA polymerase starts the synthesis of a DNA strand complementary
to the target sequence (using the four desoxynucleotides dATP, dGTP, dCTP and
dTTP) at the free 3’ end of the primer, incorporating the primer molecule in the
new DNA strand. After 30 cycles the target sequence with the flanking primer
sequences has been massively amplified and is the predominant DNA species in
the reaction. Quantitative real-time PCR is based on regular PCR technique but
offers a quantification of the PCR products at every PCR cycle. This quantifica-
tion is possible through addition of a fluorescent dye (for example: SYBR Green
I), which preferentially/specifically binds to double-stranded DNA and the use of
a fluorescence-detecting thermocycler machine. DNA binding enhances the fluores-
cence of the dye and thus allows the correlation between increase of fluorescence
and an increase of amplified PCR product in every cycle. In the presence of SYBR
Green a fluorescence signal can only be detected at the annealing/extension stage
of the PCR cycle, when double-stranded DNA molecules are created that allow
intercalation of the dye.
After PCR with SYBR Green is completed, the products can be analyzed in a
real-time PCR machine using a melting curve. In this procedure, the PCR mix-
ture is heated slowly in steps of 0.5 degree from 60°C to about 95°C and fluo-
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rescence is detected at every temperature step. Reaching the temperature point
where the double-stranded PCR product melts and DNA strands separate as the
inter-molecular hydrogen bonds are disrupted, a strong decrease in fluorescence is
detected, because the SYBR Green dye is released through separation of strands.
This decrease in fluorescence can be monitored in a derivative dissociation curve as a
sharp peak at a specific temperature, if the PCR has led to a strong enrichment of a
product of defined length and therefore has worked properly. If products of different
length or unspecific PCR products were amplified, diffuse or multiple peaks can be
detected in the derivative dissociation curve. Melting curves are used to check the
specificity of the amplification reaction. To determine the length of the amplification
product a gel electrophoresis using a DNA standard must be performed.
If two PCR reaction are compared, as in the application of allele-specific PCR,
it is crucial to ensure that the efficiency of the two reactions is equal and ideally
both reactions have an efficiency of 100%. The efficiency of a PCR reaction can be
revealed using a dilution series of template DNA (standard curve).
2.2.2 Allele-specific PCR
Allel-specific PCR (asPCR) allows the selective amplification of only one allele of an
existing SNP, by choosing an allele-specific primer whose last 3’ base is complemen-
tary to the selected SNP allele. To look at both alleles of a SNP, three primers in
summary have to be designed. The location of the both allele-specific primers (only
different in the last base) is determined by the SNP. The other primer can be used
for both reactions. The use of real-time PCR with SYBR Green and allele-specific
primers, allows to detect differences in allele content. The principle of asPCR is
depicted in figure 2.1.
For every DNA sample two reactions have to be carried out in parallel, as every
allele must be amplified separately for differentiation of allele content. The differ-
ences in allele content can be monitored in real-time PCR. Figure 2.2 displays an
amplification plot of two asPCR reactions. A single DNA heterozygous for the in-
vestigated SNP has been used as template and shows parallel amplification of both
alleles, which indicates equal amounts of both alleles, as expected. This amplifica-
tion plot also shows a comparable PCR efficiency of both reactions, as amplification
curves rise simultaneously.
To ensure a good amplification efficiency, the ideal length of the amplicon is be-
tween 90 and 140 bp. The melting temperatures of all the primers as well as their
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Figure 2.1: Principle of allele-specific PCR. (A) In appropriate distance to the SNP a conserved
region without SNPs is identified and from this region the third, common oligonu-
cleotide (ON) is chosen. (B) Allel-specific ON are designed according to the SNP
position, varying in the 3’-terminating base. (C) In a PCR reaction with all three
ON, the allele 1-specific ON will perfectly bind to the complementary strand of the
allele 1 sequence, permitting amplification with the ON in the conserved region.
However, the 3’-terminal C of the allele 2-specific ON mismatches the T of the allele
1 sequence, making amplification impossible. In case of the allele 2 sequence, only
allele 2-specific ON can initiate amplification. Modified after [94], p.128.
2 Materials and methods 19
Figure 2.2: Real-time PCR amplification plot. On the y-
axis the increase in detected fluorescence as a
measure for the created PCR product is plot-
ted in a logarithmical scale. The x-axis shows
the number of the corresponding PCR cycle.
The red line (threshold) must be set in the
exponential PCR phase (automatical or man-
ual) and allows to compare two samples us-
ing the crossing point of the threshold line and
the amplification plot, with the Ct value rep-
resenting the corresponding PCR cycle. In the
depicted amplification plot, two asPCR ampli-
fication curves of a single DNA sample het-
erozygous for the investigated SNP marker are
shown. Both PCR reactions show parallel am-
plification and Ct values are identical, indicat-
ing equal amounts of both alleles as expected
for a heterozygous sample.
GC-content should be comparable. The intention of applying asPCR to DNA pools,
is to quickly identify SNPs with relevant differences in allele frequency between the
pools. The asPCR on DNA pools can not provide genotypes but reveals differences
in allele frequencies between the pools, and therefore allows a relatively quick iden-
tification of relevant SNPs. The asPCR conditions were established on test DNA
samples and test DNA pools from healthy volunteers to save patient DNA material.
2.2.3 Selection of SNP markers for allele-specific PCR
The position of the investigated SNP markers is depicted in figure 2.3. The region
for the SNP selection comprised the LPA gene as well as the intergenic regions and
the neighboring genes LPAL2 encoding soluable lipoprotein lipase 2 and the PLG
gene, encoding plasminogen, a protein similar to Lp(a).
SNP markers were selected for the following criteria: 1. suitability of the sur-
rounding sequence for asPCR and 2. rough distribution in and around the LPA
gene 3. validated SNP marker with a MAF above 10% in Caucasians. Primers
as well as the resulting amplicons were checked for specificity by a BLAST search
on the NCBI site. Furthermore secondary structure of the amplicons under PCR
conditions (annealing temperature and ionic conditions) was checked to sort out
candidates with a presumably bad PCR efficiency due to strong hairpin structures
(using mfold version 3.2) [97]. Of 3,210 validated SNPs in the LPA gene region
(from dbSNP build 125) 12 SNPs were selected for asPCR on pooled DNA. All used
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Figure 2.3: Distribution of SNPs in the LPA gene region investigated by asPCR on DNA pools.
The position of the SNPs is depicted above the schematic representation of the 300 kb
region on human chromosome 6q27 NCBI build 35: 160,850,000-161,150,000 contain-
ing the LPA gene and its neighboring genes, LPAL2 and PLG. Underneath the LD
structure in the LPA gene region is represented, pairwise r2-values between markers
from CEU samples of HapMap project phase II release 21 (http://www.hapmap.org)
are shown with darker regions representing higher LD.
primer trios are listed in table 2.1. Prior to the experiments with pools, the primer
trios were tested on different DNA samples (from healthy volunteers) to optimize
PCR conditions and evaluate the specificity (melting curve) and efficiency (standard
curve) of the PCR reactions. Runs on test pools with defined allele content were
then performed to analyze the limits of resolution in allele frequency differences.
2.2.4 Selection and pooling of DNA samples
For 499 families with 1,298 individuals of the German MI family study, linkage
data from a total genome scan using 394 microsatellite markers were available from
a previous investigation [81]. The analysis of the microsatellite markers with the
Lp(a) serum levels led to a linkage signal at chromosome 6q27 with a LOD score of
26.99 [81]. Of these families 42 were identified as contributors to this linkage signal
(per family LOD score >0.4) and 42 families without contribution to this linkage
signal (per family LOD score <-0.2). DNA pools of MI patients that contributed
to this QTL on Lp(a) plasma levels on chromosome 6q27 and DNA pools of MI
patients that did not contribute to this QTL were investigated.
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2.2.5 asPCR procedures
All PCRs were performed on an Applied Biosystems 7900HT Real-time PCR system.
The composition of a standard asPCR reaction is listed in table 2.2.
Table 2.2: Standard asPCR reaction
total volume: 15 µl
PCR Master Mix (ABI or Qiagen) 7.5 µl
ON-1 (10 µM) 0.45 µl
ON-2 or ON-3 (10 µM) 0.45 µl
water 6.6 µl
Two different commercial PCR master mix, containing SYBR Green, were used:
Qiagen SYBR Mix (Qiagen, Hilden, Germany) and Power SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA). Three PCR runs were performed
on the DNA pools with different annealing/extension temperatures (listed in table
2.3).
Table 2.3: Thermocycling conditions of asPCR runs on DNA pools
asPCR run enzyme PCR cycles (40)
activation denaturation annealing extension
run 1
temperature(°C) 95 94 58 72
time (s) 900 15 15 20
run 2
temperature(°C) 95 94 57 72
time (s) 900 15 15 20
run 3
temperature(°C) 95 94 58 60
time (s) 900 15 15 20
Allele-specific PCR conditions for rs1652507 and rs1406888 could not be suffi-
ciently optimized and therefore patient pools were not analyzed for these two mark-
ers.
2.2.6 Analyzing the PCR data
Allele frequencies of the pooled samples were determined according to Germer et al.
[96]. The number of PCR product (y) in a PCR reaction can be obtained using the
following equation:
y = x · (1 + E)n
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with x being the initial target copy number, E the efficiency of the reaction and n
the number of PCR cycles. At 100% efficiency of the PCR reaction the equation
becomes:
y = x · 2n
which means that in a fully efficient PCR reaction the amount of PCR product
doubles at every cycle. Thus, a 2-fold dilution series of template DNA results in a
∆Ct of 1 between the samples. For DNA pools the difference in Ct between two
different PCR reactions (∆Ct) is a measure of the allele frequency. In the first step
the inter-allelic Ct difference is determined for every pool ( C= contributor pool,
N= non-contributor pool):
CtAllele 1 of Pool C − CtAllele 2 of Pool C = ∆CtPool C
The derived ∆Ct, can be either positive or negative depending on which allele
exhibits the lower Ct. A ∆Ct of one cycle, means that the ratio of one allele to the
other is 1:2, or in general:
1 : 2∆Ct
The difference in Ct can also be expressed in allele frequency, instead of ratios. To
convert a ratio to a frequency, the numerator is added to the denominator, which
results in the following formula:
frequency of allele 1 =
1
(2∆Ct + 1)
The allele frequencies are calculated for the contributor and the non-contributor
pools and compared.
2.3 Genotyping with TaqMan Assays
2.3.1 The 5’ nuclease assay
The TaqMan technique combines in a single step PCR amplification and detection
by the use of fluorogenic probes in a 5’ nuclease assay (Figure 2.4) [98].
The fluorogenic probes consist of an oligonucleotide labeled with a fluorescent
reporter at its 5’ end and a quencher dye at its 3’ end. In the intact probe the
proximity of the quencher dye reduces the fluorescence signal from the reporter
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Figure 2.4: 5’ nuclease assay. Stepwise representa-
tion of the forklike-structure-dependent,
polymerization-associated, 5’ to 3’ nu-
clease activity of Taq DNA polymerase
acting on a fluorogenic probe during one
extension phase of PCR. Two dyes, a
fluorescent reporter (R) and a quencher
(Q), are attached to the probe. When
both dyes are attached to the probe re-
porter dye emission is quenched. During
each extension cycle the Taq DNA poly-
merase cleaves the reporter dye from
the probe. Once separated from the
quencher, the reporter dye emits its
characteristic fluorescence [98].
dye. The probes are added to the PCR amplification reaction together with the
forward and reverse primer. During the annealing/extension step of PCR the labeled
probe hybridizes to the target sequence. Starting at the 3’ end of the primer, Taq
polymerase extends the amplicon until reaching the bound probe. The 5’ nuclease
activity of the Taq polymerase cleaves the probe at the 5’ end and liberates the
reporter dye from the probe. Uncoupling of the reporter dye leads to an increase in
fluorescence signal, as the proximity to the quencher dye is lost. Thus, an increase
of fluorescence indicates that the probe specific target has been amplified.
The cleavage of the probe occurs only if the probe is specifically hybridized to
its target sequence, as a mismatch promotes displacement of the probe rather than
cleavage. Therefore, the 5’ nuclease assay allows to discriminate alleles that differ
by a single base substitution, with the use of differently labeled specific probes for
each allele (Figure 2.5) [98].
As the read-out of the experiment is fluorescence, a measurement of the fluores-
cence spectrum is required after PCR. This post PCR fluorescence data detected
for every well of the PCR plate is than automatically processed by the Sequence
Detection System software (SDS) to make genotype calls. Ideally, a sample homozy-
gous for the allele detected by a FAM labeled probe should emit the fluorescence
spectrum of the FAM dye, a sample homozygous for the allele detected by a VIC la-
beled probe should emit the fluorescence spectrum of the VIC dye. A heterozygous
sample should emit the spectra of both dyes in equal intensity. In a cluster plot
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Figure 2.5: Allelic discrimination assay design strategy with fluorogenic probes in the 5’ nuclease
assay. The presence of a mismatch between probe and target reduces the efficiency
of probe cleavage. Modified after [98].
the fluorescence intensity of the different dyes is plotted for every well of the PCR
plate and the software identifies the different clusters, representing the three clouds
of possible genotypes (Figure 2.6). The TaqMan technique is especially suitable for
genotyping of large sample sets with few assays.
Figure 2.6: Cluster plot as result of allelic dis-
crimination with fluorogenic probes
in the 5’ nuclease assay. The plot
shows four clouds, the blue cloud
represents the samples homozygous
for G allele detected by the FAM
labeled probe, the green cloud rep-
resents the heterozygous samples,
and the red cloud represents the
samples homozygous for the A al-
lele detected by the VIC labeled
probe. The black cloud in the lower
left corner of the plot represents the
no template control samples.
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2.3.2 SNP selection and genotyping of individual DNA
samples
In total six SNPs of the LPA gene were genotyped with the TaqMan assays, the
SNP characteristics are given in table 2.4.
Table 2.4: SNP characteristics
absolute LPA ABI-
SNP position* Location Alleles assay ID
rs7752408 160,992,284 Intron 19 G>C C 1550878 10
+79170 G>A 160,976,489 Intron 26 G>A -
rs6923877 160,967,208 Intron 28 G>A C 103952 10
rs12207195 160,944,989 Intron 30 G>A C 407852 10
rs11751605 160,933,641 Intron 34 T>C C 282793 10
rs3798220 160,931,548 Exon 36 T>C C 25930271 10
∗ on chromosome 6, NCBI build 35
2.3.3 Standard TaqMan Assay
Individual DNA samples were genotyped using 5´ nuclease TaqMan technology (Ap-
plied Biosystems, Foster City, CA, USA) with differently fluorescence labeled probes
including non-fluorescence quencher and minor groove binder (MGB). Available Taq-
Man assays were ordered from Applied Biosystems, the assay for +79170 G>A
was designed using the Primer Express software (Applied Biosystems), producing
a 98 bp-amplicon with primer sequences for left primer: 5´CATCGGAGGATCC-
CATTAT 3´ and right primer: 5´CATGGGCCAGCTAAGAGA 3´. The following
MGB probes were used: 5´6FAM-ATAGACATACGCATTTG 3´MGB detecting the
G allele and 5´VIC-TAGACATATGCATTTGG 3´ MGB detecting the A allele. For
each genotyping reaction 10 ng of genomic DNA were applied in a 384-well plate
and dried. Then a 5 µl volume containing 2.5 µl 2xTaqMan Genotyping Master Mix
(Applied Biosystems) and the recommended amount of assay was applied to each
well. Thermocycling was performed under recommended conditions (10 min of ini-
tial denaturation at 95°C, followed by 40 cycles of 15 sec denaturation at 95°C and
a combined annealing/extension step of 1 min at 60°C) in the Applied Biosystems
7900HT Real-time PCR system or an external PCR system (GeneAmp PCR 9700,
Applied Biosystems). The post PCR endpoint plate read was carried out using the
Applied Biosystems 7900HT Real-time PCR system. Automated genotype calling
(applying the allelic discrimination test) was performed with the Sequence Detection
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System (SDS) software 2.2 from Applied Biosystems. To check for correct genotyp-
ing 20% of DNA samples were genotyped twice and no genotyping discrepancies
between the duplicates were detected. The call rates were between 98.6 and 99.4%.
2.4 Genotyping with microarrays for genome-wide
association
A microarray is a miniature array of different DNA or oligonucleotide sequences on
a glass surface that is intended to be used in hybridization assay [94]. The different
steps of the genotyping procedure with the Affymetrix GeneChip Human Mapping
500K Array Set are schematically depicted in figure 2.7. The GeneChip Human
Mapping 500K Array Set is comprised of two arrays [99]. One array uses the NspI
restriction enzyme and is capable of genotyping about 262,000 SNPs, the other array
uses the StyI restriction enzyme and is capable of genotyping about 238,000 SNPs
[99]. The median physical distance between SNPs is 2.5 kb and the average distance
between SNPs is 5.8 kb [99]. Per SNP, 24 to 40 different 25 bp- oligonucleotides
are present in the array set, the oligonucleotides are synthesized in parallel by a
photolithographic procedure [99].
Figure 2.7: Genotyping with an Affymetrix SNP Chip. After digestion of the genomic DNA with
the restriction enzyme NspI (or StyI ), adapter molecules are ligated to the DNA.
Then an amplification step, a labeling step and finally the hybridization step follow.
The fluorescence intensities of the hybridized probes are read out in a scanner, and
transferred into genotype calls with a calling algorithm [99].
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From a previous investigation for a subsample of patients from the German MI
Family Study (n=875) data from a genome-wide SNP genotyping using 500,000 SNP
markers on the GeneChip Human Mapping 500K Array Set from Affymetrix was
available [100]. The genotyping of the German samples was performed at the GSF
National Research Centre in Neuherberg (now Helmholtz Zentrum Munich, German
Research Center for Environmental Health).
2.5 Sample selection
Three different population samples were used for individual genotyping with TaqMan
assays.
Family sample from the German MI family study
The MI families were ascertained through index patients, who were identified by
screening 200,000 patient charts in 14 cardiac in-hospital rehabilitation centers dis-
tributed throughout Germany [81]. Index patients had all suffered from MI before
the age of 60 years [81]. If at least one first-degree relative had suffered from MI or
had severe coronary artery disease (percutaneous transluminal coronary angioplasty
(PTCA) or bypass surgery (CABG) before the age of 70 years), the nuclear family
was contacted and invited to participate in the study [81]. From all 7,573 persons
included in the study those with measured Lp(a) levels were selected for the present
investigation. In total 2,292 individuals from 687 families with measured Lp(a) levels
were identified in the database and the DNA samples were used for TaqMan geno-
typing. As this sample allowed only family based association testing, two subsamples
(case samples) were deduced from this family sample for a case-control association
study with an external control population. The first case sub-population, referred to
as ’Index MI patients’, consisting of 595 Index MI patients (as defined above) with
measured Lp(a) plasma levels were available for genotyping in the present study.
A second case population consisting of single siblings of index MI patients with
documented CAD was used for verification (n=471, referred to as ’affected CAD
siblings’). The study protocol was approved by Ethics Committee of the University
of Regensburg, and all participants gave informed consent.
2 Materials and methods 29
Population-based controls
As a population-based control sample, controls from the MONICA Echocardio-
graphic substudy were used. Subjects participated in the Echocardiographic Sub-
study, of the third MONICA (MONitoring of Trends and Determinants In CAr-
diovascular Disease) Augsburg Survey, which is now continued in the framework
of KORA (Cooperative Health Research in the Augsburg Area) [101]. This study
population originated from a sex- and age-stratified cluster sample of all German
residents of the Augsburg study area [102, 101]. The study design, sampling frame,
and data collection have been described in detail elsewhere [101]. The third sur-
vey represents individuals aged 25 to 74 years (mean: 51.8±13.8, including 851
(50.7%) women and 827 (49.3%) men and 300 subjects for each 10-year increment
(total n=1,674). From the 1,674 subjects, both DNA samples and Lp(a) data were
available in 975 subjects, in the following referred to as ’MONICA controls’.
Replication MI case sample
In 1996 to 1997, MI patients from the population-based MONICA MI registry Augs-
burg who had experienced their first MI before 60 years of age were examined in a
study center (n=609). MI had been verified according to standard MONICA cri-
teria [101]. Of these, 450 blood samples with measured Lp(a) levels were available
for genotyping in the present study and are referred to as ’KORA MI cases’. These
subjects served as an additional independent case population consisting of incidental
non-familial MI cases for replication of the results.
Cardiogenics sample for genome-wide association
In 2007 a genome-wide association analysis of coronary artery disease, with about
500,000 SNP markers per individual investigated, was performed in 1,926 case
subjects and 2,938 controls from the Wellcome Trust Case Control Consortium
(WTCCC) and replicated in the German MI Family Study (with 875 cases and
1,644 controls) [100]. Genotyping in both studies was performed with the use of
the GeneChip Human Mapping 500K Array Set from Affymetrix [100]. For 487 of
the investigated cases from the German MI Family Study Lp(a) levels were avail-
able from a previous investigation [52]. With this subsample of Cardiogenics cases
a genome-wide association of Lp(a) levels using the data from the Affymetix SNP
genotyping was performed.
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2.5.1 Measurement of Lp(a) levels
The Lp(a) levels used in this investigation were obtained in a previous investiga-
tion [52]. The method of measurement used in this previous investigation yielded
valid data including the result of 0 mg/dl Lp(a). Square-root transformation was
therefore used to normalize the skewed distribution of Lp(a) values. A logarithmi-
cal transformation could better harmonize the extreme high values, but also would
loose the data points at 0 mg/dl, and therefore a logarithmical transformation was
not eligible for the existing data. A new measurement of Lp(a) in all samples was
also not possible, as serum was not accessible from all samples and the age of sam-
ples could strongly influence the measurement, though in the mean time Lp(a) level
measurements have been refined.
2.5.2 Phenotypic apo(a) information and information on the
pentanucleotide repeat polymorphism
Phenotypic size of the expressed apo(a) (corresponding to the number of KIV-2
repeats) obtained by immunoblotting of serum was available for 406 Index MI pa-
tients, 355 affected CAD siblings, 678 MONICA control samples and 172 KORA MI
samples from a previous investigation [52]. Additionally, information on the num-
ber of pentanucleotide repeats in the 5’ region of the LPA gene obtained by PCR
was available for 346 Index MI patients, 301 affected CAD siblings, 693 MONICA
control samples and 414 KORA MI samples from a previous investigation [52].
2.5.3 Definitions
Cardiovascular risk factors were defined using standard criteria. Systemic arterial
hypertension was defined as a systolic blood pressure of >140 mmHg or diastolic
blood pressure >90 mmHg or the use of antihypertensive medication. Actual hy-
pertension was defined as systolic blood pressure of >140 mmHg or diastolic blood
pressure>90 mmHg. Hypercholesterolemia was defined as a documented low density
cholesterol value >130 mg/dl or the treatment with lipid lowering drugs. Diabetes
was defined as history of diabetes mellitus or the use of antidiabetic medication.
Smoking status was defined as current or former cigarette smoking on a regular
basis. Body mass index (BMI) was calculated as body weight in kilograms divided
by height in meters squared. Age is given as age at MI for Index MI patients and
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KORA MI patients, as age at onset of coronary disease for the affected CAD siblings
and as age at examination for the MONICA controls. Continuous variables in tables
are given as mean values with standard deviation unless stated otherwise.
2.6 Statistical analysis
2.6.1 Family-based association testing
Two different approaches were used for association testing in the family sample
with the quantitative trait Lp(a). Square-root transformed Lp(a) levels were used
in both tests. First the program PLINK was used, all analysis were performed with
version v0.99s [103] (http://pngu.mgh.harvard.edu/purcell/plink/). In PLINK the
QFAM procedure allows family-based tests of association with quantitative phe-
notypes. PLINK performs a simple linear regression of phenotype on genotype,
but then uses a special permutation procedure to correct for family structure. The
QFAM procedure was performed with 100,000 permutations. The other method used
is implemented in the program FBAT (Family-Based Association Tests in genetic
analyses) [104]. Similar in spirit to a classical TDT (Transmission Disequilibrium
Test), in which alleles transmitted to affected offspring are compared with the ex-
pected distribution of alleles among offspring, the approach compares the genotype
distribution observed in the ’cases’ to its expected distribution under the null hy-
pothesis. In the case of linkage the null hypothesis is: no association, in the presence
of linkage. Under the null hypothesis of “no association in the presence of linkage”
sibling marker genotypes are correlated and nuclear families can no longer be treated
as independent [105]. However, Lake et al. showed that a valid association test in
the presence of linkage is performed using the mean of the test statistic computed
via the Rabinowitz-Laird algorithm under the null hypothesis of “no association and
no linkage”, by using an empirical variance-covariance estimator that adjusts for the
correlation among sibling marker genotypes and for different nuclear families within
a single pedigree [106]. FBAT offers the -e option for association analysis in the
presence of linkage, this tools provides an option to calculate this empirical correc-
tion to the variance [106, 104]. The -e option of FBAT was used for the association
analysis in the family sample.
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2.6.2 Case-control studies
All parameters were compared between the MONICA control group and each case
group separately, using JMP 5.0.1 (SAS Institute, Cary, NC, USA). Clinical charac-
teristics were compared with a student’s t test for normally distributed continuous
variables, and the χ2 statistics for dichotomized variables. Because of skewness
of Lp(a) levels, the nonparametric Mann-Whitney U test was used for comparison
of Lp(a) levels. Lp(a) levels by genotypes were compared by the non-parametric
Kruskal-Wallis test. For each of the SNPs, the observed allele frequencies were
tested for deviation from Hardy-Weinberg proportion. Linkage disequilibrium (LD)
was assessed as r2 and D’ between all pairs of SNPs. PLINK and Haploview 4.0 were
used to assess r2 between SNPs and D’ was assessed applying the standard definition
of D’ [103, 107, 108]. Crude and adjusted logistic regression analysis was used to
assess the association of the risk allele 2 with MI and/or CAD (genotype 12 or 22
vs. 11). Adjustments have been made for age, gender, BMI, systolic blood pres-
sure, diabetes, smoking, the total cholesterol/HDL cholesterol ratio, and in separate
models additionally for square root transformed Lp(a) levels. Moreover, MI patients
were also matched with control subjects by age (±10 years) and gender by use of an
automated, randomized selection of control subjects, in order to avoid systematic
differences in genetic composition between the two groups. Using this strategy, an
appropriate control subject could be found for 473 MI patients. In this matched
case-control sample, conditional logistic regression analysis was used for testing the
association between case status and the risk allele. To test whether a particular
SNP, either directly or through LD with the QTL underlying mutation, contributes
to the evidence for linkage, each SNP under a dominant model was entered into the
QTL linkage analysis and the change in the magnitude of the LOD score calculated.
Testing for evidence of linkage to the Lp(a)-QTL on chr6q27 was done in the Index
MI cases and their affected siblings included in the present study, using the variance
component approach implemented in the SOLAR software package (version 2.1.4)
[109, 110, 111]. A two-sided P value <0.05 was considered significant.
2.6.3 Genome-wide association testing
The data from the GeneChip Human Mapping 500K Array Set were analyzed with
PLINK. Square-root transformed Lp(a) levels were used for quantitative association
tests with linear regression, in this analysis 262,314 SNP markers from the NspI
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array and 189,456 SNP markers from the StyI array were used. The results were
graphically displayed using Haploview 4.0. As a lot of SNP markers in the LPA
gene region gave strong association results with Lp(a) levels, an adjustment for these
highly significant SNPs was performed, also using PLINK. A linear model association
was calculated with square-root transformed Lp(a) levels, using the selected tagging
SNPs in a condition list. Tagging SNPs were selected using HapMap data of build
36 and the “pairwise tagging” option in Haploview 4.0.
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3 Results
3.1 Allele-specific PCR on pooled DNA samples
Of 3,210 validated SNP markers in the LPA gene region (from dbSNP build 125)
12 SNPs were selected for asPCR on pooled DNA (see 2.2.3). The allele frequencies
of the investigated SNP markers in the pool were determined according to [96], as
described in 2.2.6. Allele-specific PCR on pooled DNA samples revealed that three
SNP markers showed a difference in allele content between the contributor and non-
contributor pools. Table 3.1 shows the results of asPCR. The three SNP markers,
rs11751605, rs12207195 and rs7752408, all located within the LPA gene, showed a
marked difference in allele distribution between DNA pools of MI patients that con-
tributed (per family lod score >0.5) to a previously reported QTL on Lp(a) plasma
levels on chromosome 6q27 and (Pools A + B) MI patients that did not contribute
(per family lod score <0.5) to this QTL (Pools C + D) [81]. A difference in allele
frequency of more than 10% between the pools was considered significant. This
rather conservative relevant difference was chosen as the compared pools represent
opposite extremes of samples. For rs12207195 an exception was made, the allele
frequency difference was only 4.4%, but as the detected allele had a low frequency
(8.7% in the contributor pool and 13.1% in the non-contributor pool), and the abso-
lute difference in allele content was 1.5 fold, therefore the difference was considered
relevant.
3.1.1 SNP selection and genotyping of individual DNA
samples
To verify the results from asPCR on pooled samples, an individual genotyping us-
ing TaqMan technology was performed in the MI family study. Additionally to
the three SNP markers, rs11751605, rs12207195 and rs7752408 that had shown a
marked difference in the pooled samples, three other SNPs within the LPA gene were
chosen. One SNP, rs6923877, was identified on the Applied Biosystems homepage
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Table 3.1: Results from asPCR on contributor and non-contributor pools
mean of frequency of difference between
inter-allelic Ct allele 1 (calculated contributor and non-
difference for contributors (A+B)and contributor pools
per pool non-contributors(C+D) greater than 10%?
SNP marker run Pool (∆Ct) as 1/(2∆Ct + 1))
rs10945674 3 A 1.426 0.276 no
B 1.360
C 1.877 0.255
D 1.221
rs7453836 1 A 0.262 0.374 no
B 1.223
C 0.843 0.313
D 1.422
rs3127596 1 A 0.290 0.443 no
B 0.374
C -0.169 0.444
D 0.492
rs7775600 3 A -1.686 0.780 no
B -1.965
C -1.599 0.756
D -1.670
rs11751605 2 A -0.273 0.567 yes
B -0.504
C 0.828 0.396
D -0.219
rs12207195 1 A 3.424 0.087 no
B 3.349
C 2.676 0.131
D 2.786
rs7752408 1 A -1.718 0.800 yes
B -2.284
C -0.894 0.625
D -0.580
rs9457997 1 A -1.930 0.790 no
B -1.893
C -1.809 0.791
D -2.034
rs1950562 1 A 0.902 0.386 no
B 0.436
C 0.743 0.426
D 0.115
rs1853018 1 A -0.132 0.453 no
B 0.401
C 0.223 0.455
D 0.300
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as appropriate for TaqMan genotyping. Two more SNP markers were chosen from
the literature: rs3798220 was reported to be associated with plasma Lp(a) levels
and severe CAD and a G to A substitution at the +1 donor slice site of KIV-8
intron, with the position 79,170 relative to ATG, and the absolute position on Chr6:
160,976,489 on NCBI build 35 (in the following referred to as ’+79170G>A’ was
reported to have a strong decreasing effect on Lp(a) plasma concentration [93, 40].
The SNP characteristics are given in Table 3.2 and their position in the LPA gene
is depicted in Figure 3.1.
Figure 3.1: Schematic representation of the LPA gene structure and its LD pattern.(A) The
132.8 kb region on human chromosome 6q27 NCBI build 35: 160,922,927-161,055,702
containing the LPA gene (RefSeq NM 005577.2) with 39 exons (vertical blue lines)
oriented from right to left, SNP positions (black arrows) and repeats of KIV-2 (red
kringles) are given, as well as the kringle V domain (in green). (B) Representation
of LD structure in the LPA gene. Pairwise r2-values between markers from CEU
samples of HapMap project phase II release 21 (http://www.hapmap.org) are shown
with darker regions representing higher LD.
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Table 3.2: SNP characteristics
absolute MAF†
SNP position* Location Alleles (%)
rs7752408 160,992,284 Intron 19 G>C 37.2
+79170 G>A 160,976,489 Intron 26 G>A 2.8
rs6923877 160,967,208 Intron 28 G>A 34.7
rs12207195 160,944,989 Intron 30 G>A 13.8
rs11751605 160,933,641 Intron 34 T>C 15.1
rs3798220 160,931,548 Exon 36 T>C 2.2
∗ on chromosome 6, NCBI build 35
† minor allele frequency calculated for all 2,491 individually genotyped samples from the case/control investigation
3.2 Results from individual genotyping in the MI
family study
3.2.1 Characteristics of the family sample
In total 2,292 individuals from 760 families (with up to 11 members) with measured
Lp(a) levels were identified in the database and the DNA samples used for TaqMan
genotyping.
Baseline characteristics
The clinical characteristics of the family sample are given in table 3.3. The median
of Lp(a) levels was 14.4 mg/dl, with a 25% - 75% quantile range of 5.9 to 54.0 mg/dl.
The median of square-root transformed Lp(a) levels was 3.80 mg/dl, with a 25% -
75% quantile range of 2.43 to 7.35 mg/dl.
Genotype distribution
The distribution of genotypes obtained by TaqMan genotyping in the family sample
is given in table 3.4.
To use the full information from 2,292 genotypes for an association test with Lp(a)
levels, the method of family-based association testing had to be applied. Here, the
family structure of the sample and therefore the dependence of genotypes, is taken
into account. Otherwise only a subsample comprised of one individual per family
could have been analyzed.
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Table 3.3: Clinical characteristics of the family sample
Family sample
Variables (n=2,292)
Age, y (SD) 58.9 ± 10.7
Women, n (%) 35.3
Body Mass Index, kg/m2 (SD) 27.0 ± 3.5
Systolic BP, mm Hg (SD) 141.6 ± 21.3
Diastolic BP, mm Hg (SD) 83.8 ± 11.1
Arterial hypertension, n (%) 88.1
Actual hypertension, n (%) 45.4
Diabetes mellitus, n (%) 13.6
Former or current smoking, n (%) 63.8
LDL, mg/dl (SD) 163.4 ± 45.7
Total/HDL cholesterol ratio (SD) 5.0 ± 2.1
Hypercholesterolemia, n (%) 92.1
Myocardial infarction, n (%) 52.1
Table 3.4: Distribution of genotypes in the family sample
Alleles 11 12 22
SNP (1>2) (%) (%) (%)
rs7752408 G>C 40.0 46.6 14.4
+79170 G>A G>A 95.1 4.8 0.1
rs6923877 G>A 42.4 45.0 12.6
rs12207195 G>A 72.7 25.2 2.2
rs11751605 T>C 69.7 28.2 2.1
rs3798220 T>C 94.7 5.2 0.04
11: homozygous for the major allele, 12: heterozygous, 22: homozygous for the minor allele
3.2.2 Family-based association testing
Two different statistic programs were used to analyze the association between SNP
markers and Lp(a) levels in the family sample. The Lp(a) levels were square-root
transformed to harmonize the skewed distribution. First the genotype data and
Lp(a) levels were analyzed using FBAT (Family-Based Association Tests in genetic
analyses)[106]. In this program the -e option allows to test for association in the
presence of linkage (see 2.6.1), and this option was used as linkage of the LPA gene
region and Lp(a) levels had already been shown: The analysis of microsatellite mark-
ers (394 microsatellite markers investigated on 499 families with 1,298 individuals of
the German MI family study) with the Lp(a) serum levels led to a linkage signal at
chromosome 6q27 with a LOD score of 26.99 [81]. Results of the family-based asso-
ciation testing using FBAT are shown in table 3.5. All investigated markers showed
significant association with Lp(a) levels. To confirm the FBAT results the program
PLINK was used [103]. In PLINK the QFAM procedure allows family-based tests of
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association with quantitative phenotypes (see 2.6.1). The results from the PLINK
analysis are also shown in table 3.5. With PLINK all investigated SNP markers
showed significant association with Lp(a) levels, and P values are well comparable
to the FBAT results in size of significance. The significant results from the family-
Table 3.5: Results from family-based association testing with square-root trans-
formed Lp(a) levels as a quantitative trait
SNP marker FBAT P values * PLINK P values †
rs3798220 3.4 E-6 1.0 E-5
rs11751605 3.1 E-6 1.0 E-5
rs12207195 8.8 E-3 2.2 E-2
rs6923877 1.8 E-5 1.0 E-5
+79170 G>A 5.6 E-3 3.6 E-3
rs7752408 2.3 E-6 1.0 E-5
* from empirical variance statistic using -e option
† empirical P values of QFAM after permutation
based association analysis of SNP markers with Lp(a) levels gave further hints that
variations influencing the Lp(a) levels had been identified. To confirm this finding,
the SNP genotypes were used in a contribution to linkage analysis, where also the
strongest known factor modifying the Lp(a) levels, the KIV-2 repeat polymorphism,
was taken into account.
3.2.3 Contribution to the evidence of linkage
To assess the contribution to linkage with Lp(a) levels, individual SNPs were used
as covariates in variance-component linkage analysis of 471 sibpairs. The largest
change in the maximum LOD score (MLS) occurred with SNP rs11751605. Initially,
the peak for Lp(a) had an MLS of 8.9 at 161 cM on chromosome 6q27 in our subset
of affected siblings genotyped for this SNP. After adjustment for SNP rs11751605,
the LOD score change was a decrease to an MLS of 7.5 following a dominant model
(table 3.6).
This decrease did also reach statistical significance (P<0.05). The proportion of
variance due to SNP rs11751605 as covariate was 5% compared to 44% when KIV-2
repeats were included in the model. As expected inclusion of KIV-2 repeats led to a
marked decrease in the MLS to 4.3. In a model that included both SNP rs11751605
and KIV-2 repeats, both covariates were independently associated with Lp(a) levels
leading to a decrease in the MLS of 3.6.
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Table 3.6: Lp(a) QTL linkage analysis on chromosome 6q27 with SNP rs11751605
and/or KIV-2 included as covariates
Model Position MLS* Proportion P Value
(cM) variance due
to covariates
crude 161 8.9 - -
rs11751605 adjusted 160 7.5 5% <0.00001
KIV-2 adjusted 162 4.3 44% <0.00001
rs11751605 and 0.015
KIV-2 adjusted 160 3.6 45% and <0.00001
*MLS, maximum LOD score
From this analysis SNP marker rs11751605 had shown the strongest effect on
Lp(a) levels of all investigated SNP markers, but further evidence from independent
samples was needed. First a sample from the general population was investigated,
this allowed also to perform a case-control study on the association of MI and the
SNP markers. Second, an independent sample of incidental, non-familial MI cases
from the Augsburg area was investigated.
3.3 Case-control association samples
In total four samples were used for case-control association studies. Three case
populations were compared to the population-based control sample. KORA MI
patients were used as a independent sample of incidental, non-familial MI cases.
Two case population were deduced from the Regensburg MI family sample: one
case sub-population, referred to as ’Index MI patients’, consisted of 595 Index MI
patients, the second case population (n=471), referred to as ’affected CAD siblings’,
consisted of single siblings of index MI patients with documented CAD. This sample
of siblings was used for verification.
3.3.1 Genotyping in the population-based sample
As a population-based control sample, subjects from the MONICA Echocardio-
graphic substudy were used (see 2.5). From the 1,674 subjects, both DNA samples
and Lp(a) data were available in 975 subjects, which were genotyped. The distribu-
tion of genotypes is given in table 3.7.
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Table 3.7: Distribution of genotypes in case-control samples
Alleles MONICA controls Index MI patients affected CAD siblings KORA MI cases
(1>2) n=975 n=595 n=471 n=450
% % % %
rs7752408 G>C
11 37.7 41.6 40.3 -
12 48.5 44.4 45.9 -
22 13.8 14.0 13.8 -
+79170 G>A G>A
11 93.2 95.6 95.1 94.4
12 6.8 4.4 4.7 5.6
22 0.0 0.0 0.002 0.0
rs6923877 G>A
11 40.7 43.8 44.1 -
12 47.4 44.0 44.8 -
22 11.9 12.2 11.1 -
rs12207195 G>A
11 75.4 76.1 71.8 -
12 22.0 22.2 26.1 -
22 2.6 2.2 2.1 -
rs11751605 T>C
11 76.2 68.3 69.2 71.6
12 22.2 29.5 28.4 25.1
22 1.7 2.2 2.4 3.3
rs3798220 T>C
11 97.4 93.3 93.4 97.5
12 2.6 6.5 6.6 2.3
22 0.0 0.2 0.0 0.2
11: homozygous for the major allele, 12: heterozygous, 22: homozygous for the minor allele
3.3.2 Individual genotyping in the KORA MI sample
This sample comprised MI patients (n=609) from the population-based MONICA
MI registry Augsburg who had experienced their first MI before 60 years of age
(see 2.5). Of these, 450 blood samples with measured Lp(a) levels were available
for genotyping in the present study. In this sample only rs11751605, rs3798220 and
+79170 G>A were investigated and genotypes are listed in table 3.7.
3.3.3 Genotype distribution in the subsamples from the family
sample for association testing
The genotype distribution in the subsamples of Index MI patients and affected CAD
siblings is given in table 3.7. From table 3.7, a marked difference in allele distribution
between the samples can be seen for the markers: +79170 G>A, rs11751605, and
rs3798220.
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Table 3.8: Clinical characteristics of case-control study populations
MONICA controls Index MI patients affected CAD siblings KORA MI patients
Variables (n=975) (n=595) (n=471) (n=450)
Age, y (SD) 49.7 ±14.1 50.0 ±8.4 57.8 ±9.5‡ 56.6 ±7.1‡
Women, n (%) 49.7 13.1‡ 20.8‡ 11.1‡
Body Mass Index, kg/m2 (SD) 26.6 ±4.0 27.2 ±3.3† 26.9±3.2 28.3 ±3.7‡
Systolic BP, mm Hg (SD) 133.7 ±19.7 139.0 ±19.1‡ 144.4 ±21.6‡ 132.8 ±17.1
Diastolic BP, mm Hg (SD) 80.4 ±11.6 83.3 ±10.6‡ 84.1 ±11.5‡ 84.4 ±10.4‡
Arterial hypertension, n (%) 43.7 92.9‡ 93.3‡ 98.9‡
Actual hypertension, n (%) 37.9 53.7‡ 59.2‡ 40.8
Diabetes mellitus, n (%) 3.8 14.7‡ 15.3‡ 15.1‡
Former or current smoking, n (%) 56.9 77.3‡ 71.1‡ 78.4‡
LDL, mg/dl (SD) 142.3 ±44.0 161.8 ±45.6‡ 164.9 ±45.1‡ 134.2 ±38.4‡
Total/HDL cholesterol ratio (SD) 4.7 ±1.7 5.2 ±1.7‡ 5.0 ±1.7‡ 5.3 ±2.1‡
Hypercholesterolemia, n (%) 58.4 95.4‡ 93.6‡ 75.6‡
† P < 0.01 vs. controls;
‡ P < 0.001 vs. controls
3.3.4 Clinical characteristics of the case-control study
populations
The clinical characteristics of study populations are shown in table 3.8. The relative
frequency of female subjects was higher in MONICA controls than in all other study
populations. Furthermore, MONICA controls were slightly younger than Index
MI patients, and significantly younger than affected CAD siblings and KORA MI
patients. In each study population, Lp(a) levels were comparable in men and women.
As expected, cardiovascular risk factor distribution was more pronounced in cases
than controls. Mean Lp(a) levels were significantly lower in controls (median 11.8
mg/dl, 25% - 75% quantile range: 0.0 to 26.4) compared to Index MI patients
(median: 14.8 mg/dl, 25% - 75% quantile range: 5.9 to 64.6), affected CAD siblings
(median: 14.5 mg/dl, 25% - 75% quantile range: 5.9 to 51.0) and incident KORA
MI patients (median: 16.0 mg/dl, 25% - 75% quantile range: 5.5 to 58.0) (depicted
in figure 3.2).
As reported before, the number of expressed KIV-2 repeats showed a strong asso-
ciation with Lp(a) levels across all populations studied, when the number of KIV-2
was dichotomized to ≤21 and >21 KIV-2 repeats, respectively (figure 3.3) [52].
3.3.5 Association of individual SNP markers with Lp(a) levels
A strong association between individual SNP genotypes and Lp(a) levels could
be seen. Consistent association in each population was observed for rs11751605,
rs3798220 and the +79170 G>A SNP (table 3.9). As SNP markers rs3798220 and
+79170 G>A were rare, the maximum number of one homozygous carrier of the rare
allele was observed per population. The rare SNP markers rs3798220 and +79170
G>A showed a strong association. The most robust association was revealed for
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Table 3.9: SNP genotypes and the corresponding median Lp(a) levels (mg/dl) with
25% to 75% quantile range in all populations
MONICA controls
11 12 22
rs7752408 13.5 [1.8-37.6] 11.3 [1.8-23.1] 10.7 [6.4-15.1]
P Value* 0.0189
+79170 G>A 12.2 [1.8-26.9] 1.8 [0-14.4] -
P Value 0.0004
rs6923877 11.5 [6.6-16.8] 11.3 [1.8-23.2] 13.1 [1.8-35.1]
P Value 0.2238
rs12207195 11.8 [1.8-28.8] 12.0 [1.8-21.1] 9.1 [0-17.85]
P Value 0.1383
rs11751605 11.5 [1.8-21.5] 13.4 [1.8-48.4] 46.6 [2.5-80.0]
P Value 0.0024
rs3798220 11.6 [1.8-24.7] 101.0 [9.35-133.1] -
P Value <0.0001
Index MI patients
11 12 22
rs7752408 26.0 [7.3-84.4] 13.9 [5.9-60.5] 9.0 [5.1-15.4]
P Value* <0.0001
+79170 G>A 16.0 [6.3-66.8] 5.6 [1.2-16.3] -
P Value 0.0002
rs6923877 9.7 [5.3-18.5] 13.5 [5.9-60.1] 23.2 [6.2-81.6]
P Value 0.0004
rs12207195 16.0 [6.3-68.3] 12.6 [5.2-47.9] 15.4 [9.2-28.5]
P Value 0.1874
rs11751605 12.4 [5.6-41.3] 48.9 [7.1-80.8] 60.3 [7.9-89.6]
P Value <0.0001
rs3798220 13.7 [5.6-55.0] 109.5 [85.7-134.1] 168.6 [168.6-168.6]
P Value <0.0001
affected CAD siblings
11 12 22
rs7752408 21.4 [7.0-77.9] 13.7 [5.5-43.6] 9.3 [5.1-16.7]
P Value* 0.0004
+79170 G>A 14.5 [6.0-51.8] 8.0 [0.6-36.5] 7.4 [7.4-7.4]
P Value 0.1540
rs6923877 9.8 [5.8-18.3] 13.9 [5.2-45.8] 19.1[6.7-74.7]
P Value 0.0055
rs12207195 15.3 [6.1-60.0] 13.7 [4.7-34.3] 7.6 [3.7-33.0]
P Value 0.1586
rs11751605 13.4 [5.8-33.2] 23.7 [6.1-72.5] 87.3 [34.5-109.2]
P Value 0.0001
rs3798220 14.2 [5.7-39.1] 120.6 [87.2-160.0] -
P Value <0.0001
KORA MI patients
11 12 22
rs7752408 n.d. n.d. n.d.
P Value*
+79170 G>A 17.0 [6.0-63.5] 2.0 [1.0-13.5] -
P Value <0.0001
rs6923877 n.d. n.d. n.d.
P Value
rs12207195 n.d. n.d. n.d.
P Value
rs11751605 14.0 [5.0-34.8] 55.5 [7.0-84.3] 71.0 [29.0-119.0]
P Value <0.0001
rs3798220 15.0 [5.0-55.0] 118.0 [111.5-156.0] 323.0 [323.0-323.0]
P Value <0.0001
*P values from non-parametric Kruskal-Wallis-Test for comparison of Lp(a)levels by genotypes
11: homozygous for the major allele, 12: heterozygous, 22: homozygous for the minor allele, n.d.: not determined
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Figure 3.2: A: Comparison of mean Lp(a) levels between control and MI/CAD study populations.
Median Lp(a) levels (mg/dl) with 25% to 75% quantile range are shown for each
study population. B: Influence of KIV-2 repeat number on Lp(a) levels in each study
population. Median Lp(a) levels with 25% to 75% quantile range are given according
to KIV-2 repeats ( ≤ 21 or > 21 repeats).
rs11751605. Specifically, a marked increase of Lp(a) levels with the number of C al-
leles of rs11751605 could be observed. This increase was consistent in all populations
but at higher levels in subjects with MI/CAD.
3.3.6 Interaction between SNP markers and KIV-2 repeats on
Lp(a) levels
A test for interaction between the identified SNP markers and the number of KIV-2
repeats was performed (figure 3.3).
In individuals with ≤21 KIV-2 repeats (high Lp(a) levels) homozygosity for the C
allele of SNP rs11751605 leads to a further increase of Lp(a) levels. This effect was
consistent in subjects from the general population as well as in Index MI patients.
Interaction analysis for the rare SNP markers rs3798220 and +79170 G>A was
not possible, due to the small number of heterozygous individuals and the single
observations of homozygous carriers of the rare allele.
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Figure 3.3: Interaction between KIV-2 repeat number and rs11751605 genotype and the influence
on Lp(a) levels. The interaction plots display Lp(a) levels of subjects with ≤ 21
and > 21 KIV-2 repeats on the x-axis with separate lines for the means of each
genotype of SNP rs11751605 (CC genotype indicated by ’+’, CT by ’×’ and TT by
’]’). Significant overall interactions between the SNP and the KIV-2 repeat number
could be revealed in controls from the MONICA general population (left) and in
Index MI cases (right). Homozygosity for the C allele of SNP rs11751605 leads to a
significant increase in Lp(a) levels compared to CT or TT allele carriers when ≤ 21
KIV-2 repeats are present, also in both populations.
3.3.7 Association of SNP markers with MI
SNP marker rs11751605 was tested for association with MI and/or CAD. A signif-
icant difference (P=0.001) in the allele frequency of the minor allele (C allele) was
observed between healthy subjects from the general MONICA population (12.8%)
and Index MI patients (17.0%), with an odds ratio (OR) of 1.4; 95% confidence in-
terval (CI) 1.14 to 1.70. Using a dominant model, a strong association of MI with C
alleles of rs11751605 (OR, 1.48; 95% CI, 1.18 to 1.86, P=0.0008) was found. When
adjusting for the potential confounders, age, sex, BMI, systolic blood pressure, dia-
betes mellitus, smoking, and total/HDL cholesterol ratio, the association remained
significant (OR, 1.58; 95% CI, 1.22 to 2.05, P=0.0006). After additional inclu-
sion of the square root transformed Lp(a) levels, a trend for association remained,
though the level of significance could not be reached (OR, 1.28;95% CI, 0.97 to 1.68,
P=0.079, Figure 3.4). Due to age and gender differences between Index MI patients
and MONICA controls additionally an age- and sex matched sample was analyzed,
including 473 Index MI patients and 473 MONICA controls. Here the risk increase
by the C-allele of rs11751605 was comparable to the overall sample (OR, 1.65; 95%
CI, 1.24 to 2.22, P=0.0008) using conditional logistic regression. Similar to the
overall sample the risk increase for MI remained when accounting for cardiovascular
risk factors and square root transformed Lp(a) levels (OR, 1.36; 95% CI, 0.99 to
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1.89). These effects could be confirmed using KORA MI patients and affected CAD
siblings (figure 3.4).
Figure 3.4: Odds ratios from logistic regression analysis for MI and CAD according to rs11751605
genotypes. Odds ratios with 95% CI and P values are given as three different ad-
justments of the dominant model (CC+CT vs. TT): adjustment for sex and age,
multivariate adjustment (age, sex, BMI, systolic blood pressure, diabetes mellitus,
smoking, total cholesterol/HDL ratio), and multivariate adjustment additionally in-
cluding square root transformed Lp(a) levels.
For marker rs3798220 an association with MI could be detected in allele frequency
of the rare C allele between MONICA controls and Index MI patients (P=0.0002).
This association remained significant after adjustment for the risk factors, age, sex,
BMI, systolic blood pressure, diabetes mellitus, smoking, and total/HDL cholesterol
ratio (OR, 2.74; 95% CI, 1.54 to 4.98, P=0.0007). After additional inclusion of the
square root transformed Lp(a) levels, the association did not remain, and the level
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of significance was clearly failed (OR, 1.28; 95% CI, 0.68 to 2.44, P=0.43). The
association of rs3798220 with CAD could also be seen in comparison of MONICA
controls with affected CAD siblings (P=0.0004; OR, 2.66; 95% CI, 1.56 to 4.60)
and the association remained significant (P=0.01; OR, 2.26; 95% CI, 1.12 to 4.23)
after risk factor adjustment (risk factors as given above). When KORA MI cases
were compared with MONICA controls, rs3798220 failed to show association with
MI (P=0.9; OR, 0.96; 95% CI, 0.45 to 1.92). Therefore, no consistent association
of rs3798220 genotype with MI could be shown.
3.4 Linkage disequilibrium analysis and
Hardy-Weinberg proportions
SNP markers are transmitted in blocks, a measure of this block structure is LD,
the linkage disequilibrium [112]. Between two SNP markers this can be expressed
by the correlation coefficient r2 [112]. LD between the investigated SNP markers
was analyzed (in terms of r2) and a two block structure was found, that reflects
the LD structure of HapMap in CEPH samples, as shown in figure 3.1 [113, 114].
These data indicate that rs7752408, SNP +79170 G>A, and rs6923877 are in LD
with the KIV-2 repeat polymorphism. In contrast, there was only marginal LD be-
tween rs11751605, rs12207195 and the KIV-2 repeat polymorphism. All SNPs were
tested for Hardy-Weinberg proportions and all genotypes fulfilled Hardy-Weinberg
expectations. Deviations from HW equilibrium can indicate inbreeding, population
stratification or problems in genotyping [115].
3.5 Genome-wide association testing
3.5.1 Characteristics of the subsample with GWA data
For a subsample (n=487) of the Cardiogenics patients with GWA data, Lp(a) levels
were available. These samples had been genotyped with GeneChip Human Mapping
500K Array Set from Affymetrix (comprised of two arrays: StyI and NspI ). The
baseline characteristics of this Cardiogenics sub-sample are given in table 3.10. The
sample was comprised of MI patients only. The median Lp(a) level was 16.0 mg/dl,
with a 25% - 75% quantile range of 6.8 to 65.9 mg/dl.
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Table 3.10: Clinical characteristics of the Cardiogenics sub-sample
Cardiogenics sub-sample
Variables (n=487)
Age, y (SD) 50.2 ± 7.9
Women, n (%) 33.5
Body Mass Index, kg/m2 (SD) 27.3 ± 3.5
Systolic BP, mm Hg (SD) 142.3 ± 21.0
Diastolic BP, mm Hg (SD) 84.2 ± 10.5
Arterial hypertension, n (%) 92.3
Actual hypertension, n (%) 47.8
Diabetes mellitus, n (%) 16.1
Former or current smoking, n (%) 70.4
LDL, mg/dl (SD) 162.2 ± 46.2
Total/HDL cholesterol ratio (SD) 5.1 ± 1.7
Hypercholesterolemia, n (%) 96.1
3.5.2 Quantitative association analysis
The genome-wide data were analyzed using PLINK. A quantitative association anal-
ysis was performed using square-root transformed Lp(a) levels. From the 262,314
SNP markers of the NspI array, 12,725 SNPs failed the missingness test (excluding
SNP with more than 10% missing genotypes) and 33,105 SNPs failed the frequency
test (excluding SNPs with a minor allele frequency below 0.01). The remaining
216,546 SNP markers from the NspI array were used for the quantitative associ-
ation analysis in PLINK, the total genotyping rate was 97.8%. For the 238,354
markers of the StyI array, 19,212 were excluded for low genotyping rate and 26,694
SNPs were excluded for low minor allele frequency. For the analysis, 189,456 markers
from the StyI array were used, resulting in a genotyping rate of 97.2%.
Figure 3.5 displays graphically the results from the quantitative association of the
SNP markers with square-root transformed Lp(a) levels. The plot was created using
Haploview 4.0.
For chromosome 6 a peak of SNP markers that is highly associated with square-
root transformed Lp(a) levels can be seen. These strong association signals emerge
from the region around the LPA gene. Marker SNP A-4285662 (= rs2048327),
located within the SLC22A3 gene, a neighbor of the LPA gene, showed the strongest
association with square-root transformed Lp(a) levels providing a P value of 2.4
E-10. This P value can be considered as genome-wide significant, when using the
Bonferroni approach of dividing the commonly used P value of 0.05 by the number of
tested markers, in this case: 500,000. When a threshold of genome-wide significance
of 1.0 E-7 is applied, eight SNP markers, all markers located in the LPA gene region,
show genome-wide significant association with square-root transformed Lp(a) levels.
In total 3,759 SNP markers showed association with square-root transformed
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Figure 3.5: P values on the y-axis are displayed as minus log P, chromosome number is given
on the x-axis.
Lp(a) levels with a P value below 0.05. Of these markers, 379 SNP markers showed
association with a P value below 0.001. 99 of these 379 markers are located on chro-
mosome 6, but also on several other chromosomes, as chromosome 8 (36 markers)
and chromosome 11 (23 markers) associated markers were identified.
3.5.3 Results for the SNPs from the LPA gene region
A detailed view on the results from the genome-wide association for the LPA gene
region is given in figure 3.6.
Only 13 SNPs located within the LPA gene show association with square-root
transformed Lp(a) levels, of 18 SNPs (from both arrays) located within the LPA
gene. Of these 18 SNPs only 11 SNPs had good cluster plots, which means that the
genotype clusters could be distinguished properly. Therefore, SNP markers from
the GeneChip Human Mapping 500K Array Set did not strongly improve the SNP
coverage within the LPA gene itself.
The strongest associated SNPs are located in three haploblocks (indicated by ∗
in figure 3.6). These three haploblocks originate in the LPA gene itself, as indi-
cated by the HapMap data. LD analysis of the SNP markers from the GeneChip
Human Mapping 500K Array Set in the LPA gene region showed a distribution of
haploblocks equivalent to the HapMap data. Furthermore, an interaction analysis
between SNP markers of the 500K array and the KIV-2 repeats revealed significant
interaction of SNP markers in the middle of the indicated (∗) blocks and the KIV-2
repeat polymorphism (figure 3.6). No interaction was found between SNPs located
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Figure 3.6: A: P values of association for markers of the LPA gene region from the 500K chip
with square-root transformed Lp(a) levels are displayed as minus log P on the y-
axis. B: Position of SNP markers investigated with TaqMan assays: rs11751605,
rs12207195, rs6923877 and rs7752408 (from left to right). C: Position of RefSeq genes
in the LPA gene region, displayed in UCSC March 2006 assembly, Chr6: 160,000,000-
162,000,000. D: Representation of LD structure in the LPA gene region, pairwise r2
values between markers from CEU samples of HapMap project II phase release 21
are shown with darker regions representing higher LD. The three haploblocks of the
LPA gene are indicated by ∗
in the left of the indicated haploblocks and the KIV-2 repeat polymorphism (figure
3.6).
3.5.4 Adjustment of the GWA data for the significant SNPs
from the LPA gene region
Linkage analysis identified several other loci of the genome that have been linked to
Lp(a) levels [81, 82]. Previous linkage data from our family study indicate that a
locus on chromosome 1 (closest micro-satellite marker D1S1679, with a LOD score
of 3.81) is also linked to Lp(a) levels [81]. Other, multiple QTL (apart from LPA)
influencing the serum Lp(a) concentration have been identified on chromosomes 11,
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13, 15 and 19 in an other genome-wide linkage screen [82]. These QTL regions
were identified after taking into account the strong effect detected on chromosome
6 [81, 82]. For this reason an adjustment for those SNP markers giving the strong
association result in the LPA gene region was performed on the genome-wide SNP
data. To allow a computable adjustment of the huge genome-wide data set, a subset
of tagging SNPs (representing the three haploblocks in the LPA gene region) had to
be selected.
Identification of tagging SNPs in the LPA gene region
A tagging SNP represents the information from the neighboring SNP markers when
they are transmitted together in a block of markers. The selection of tagging SNPs
was performed from HapMap data of build 36. The genotype data of the LPA gene
region on chr6: 160,650,001-161,280,000 on NCBI build 36 were downloaded and
analyzed in Haploview, where the three LD block structure (shown in figure 3.6)
appeared. In Haploview, those SNP markers with an LD of r2 > 0.8 were selected
with pairwise tagging. The list of 708 SNP markers was exported and matched with
a list of HapMap SNP markers present on the GeneChip Human Mapping 500K
Array Set and 88 possible tagging SNPs remained. With this large number of SNPs
an adjustment using PLINK was not possible and the number of SNPs was manually
reduced to 31 SNPs, 13 from the NspI array and 18 from the StyI array, listed in
table 3.11. The distribution of selected tagging SNPs is depicted in figure 3.7.
chr6:
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rs3123636
rs9456538
rs2457577
rs1567442
rs2504923
rs3127599
rs9346818
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Figure 3.7: Distribution of tagging SNPs. The position of 31 selected tagging SNPs, that capture
the three LD blocks underlying the LPA gene are shown in UCSC genome browser
on build 36.
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Table 3.11: List of tagging SNPs
Affymetrix SNP identifier 500K Chip absolute position on Chr 6* rs number†
SNP A−2183575 StyI 160,756,396 rs2457572
SNP A−4299085 StyI 160,762,527 rs3123636
SNP A−1803733 StyI 160,773,383 rs9456538
SNP A−2248891 StyI 160,774,128 rs2457577
SNP A−1988377 NspI 160,777,305 rs1567442
SNP A−2259393 NspI 160,801,498 rs2504923
SNP A−1961463 StyI 160,827,124 rs3127599
SNP A−1826864 StyI 160,834,450 rs9346818
SNP A−2272818 StyI 160,880,349 rs6919346
SNP A−1795611 NspI 160,889,728 rs10755578
SNP A−2264009 StyI 160,900,320 rs6415084
SNP A−4255889 StyI 160,918,138 rs3798221
SNP A−2237752 StyI 160,990,860 rs7760585
SNP A−2180871 NspI 161,002,685 rs1367211
SNP A−2055441 NspI 161,003,623 rs9347438
SNP A−2254455 StyI 161,017,268 rs12523781
SNP A−1824552 NspI 161,039,229 rs783144
SNP A−1831715 NspI 161,041,380 rs2144723
SNP A−4266065 StyI 161,043,175 rs1950562
SNP A−4227819 NspI 161,048,937 rs1652508
SNP A−4201898 NspI 161,057,769 rs14224
SNP A−2012234 StyI 161,063,366 rs4252117
SNP A−1898098 StyI 161,095,711 rs4252200
SNP A−2244463 NspI 161,117,058 rs1620969
SNP A−2100761 StyI 161,128,376 rs1247568
SNP A−1830392 StyI 161,149,787 rs783155
SNP A−4212106 NspI 161,168,127 rs1782634
SNP A−1943498 StyI 161,217,714 rs2489945
SNP A−2128791 StyI 161,254,404 rs1247317
SNP A−2124265 NspI 161,260,672 rs1247359
SNP A−2054021 NspI 161,279,548 rs687701
*UCSC March 2006 assembly
† dbSNP build 126
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The adjustment procedure was performed with PLINK. A linear model associa-
tion was calculated with square-root transformed Lp(a) levels, using the selected 31
tagging SNPs in a condition list. The results were displayed using Haploview 4.0
and are depicted in figure 3.8 for chromosome 6 and genome-wide in figure 3.9.
Figure 3.8: Results for chromosome 6 from genome-wide association of Lp(a) levels, adjusted for
LPA tagging SNPs
For chromosome 6 the significant association signals for association with square-
root transformed Lp(a) levels from the LPA gene region have vanished. After ad-
justment the P values for genome-wide association with square-root transformed
Lp(a) levels dropped markedly, reaching the maximum of 2.16 E-5 for the marker
SNP A-2219110 (= rs10017198) on chromosome 4. This marker does not map to a
gene, the closest gene is DHX15, a member of the DEAD box protein family and
putative ATP-dependent RNA helicase. In total 388 SNP markers provided asso-
ciation signals with P values below 0.001. Most of these SNPs (40) are located on
chromosome 8. The number of markers on the chromosomes with described linkage
is lower: only 24 of these SNP markers are located on chromosome 1, 15 markers
are on chromosome 11, 11 markers on chromosome 13, 8 markers on chromosome
15 and 5 markers on chromosome 19.
3.5.5 Regions of interest for further association analysis
For the chromosome 1 region of the previously identified QTL on serum Lp(a) levels,
no enhancement of association results could be obtained through the adjustment.
In this region (chromosome 1, 156,380,000-161,800,000 on NCBI build 35), five SNP
markers were associated (P between 0.001 and 0.0001) before the adjustment and
only two SNP markers (P between 0.001 and 0.0001) after the adjustment. One of
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Figure 3.9: Results from genome-wide association of Lp(a) levels adjusted for LPA tagging SNPs
the markers, SNP A-1860563 (= rs400214), showed association in the unadjusted
analysis as well as in the adjusted analysis. This marker is located near the CD1D
gene, encoding a member of the CD1 family of transmembrane glycoproteins. These
association results have not been replicated so far. Other promising regions, includ-
ing markers located in regions with previously described linkage (on chromosomes
11, 13, 15 and 19) have to be analyzed in detail.
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4 Discussion
Lp(a) levels are highly heritable (heritability >90%[81]) and the apo(a) locus on
chromosome 6q27 has been proven in several linkage studies as the major deter-
minant of Lp(a) serum levels [81, 82]. Elevated Lp(a) levels have been identified
as a risk factor for atherosclerosis and myocardial infarction [70]. Consequently,
polymorphisms of the LPA gene have been identified and explain one part of the
variation in Lp(a) levels in Caucasians [73]. Nevertheless, a significant proportion
of the genetic variation of Lp(a) levels remains unexplained.
4.1 Association of single SNP markers with MI and
Lp(a) levels
For complex diseases, investigators mapped the phenotype of interest first by linkage
analysis, followed by association analysis in regions with evidence for linkage [116,
117, 118]. A pooling strategy has been proposed as a way to identify meaningful
allele frequency differences in regions of linkage [96, 119], and was successfully used
in the present investigation to identify SNP markers associated with Lp(a) serum
levels. A positive replication of the findings from the pooling approach in different
samples underlines the robustness of the results. Therefore, it can be stated, that
a pooling approach using identical-by-descent (IBD)-sharing information from a
linkage analysis is a cost effective and practical way to identify relevant SNP markers
by differences in allele frequency.
In particular, association of the SNP rs11751605 could be detected with elevated
Lp(a) serum levels in patients with a history of premature MI, in MI patients with-
out such a history, and in subjects from a healthy population based sample as well.
Moreover, a strong association of the C allele of rs11751605 and MI and CAD inde-
pendently from traditional cardiovascular risk factors across these populations was
found.
The influence of the KIV-2 repeat polymorphism was considered in the present in-
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vestigation, by genotying individuals with known apo(a) isoform size (corresponding
to the number of expressed KIV-2 repeats), as this polymorphism has been described
to account for about 50% of the variability of Lp(a) levels [120, 28]. It turned out,
that both polymorphisms (KIV-2 and rs11751605) act somewhat independently as
revealed by LD mapping, interaction analysis, and the observation of an additive
contribution to the evidence of linkage. On the other hand, the present study clearly
corroborates the KIV-2 repeat polymorphism as the major contributor of Lp(a) con-
centrations.
4.1.1 Influence of previously described rare SNP markers
An association of the rare A allele of the +79170 G>A SNP was observed with
lower Lp(a) levels. Only 5.6 % of the individuals were heterozygous for this SNP
and only one individual out of 2,491 (0.04%) was a homozygous carrier of the A
allele. From the literature higher allele frequencies had been expected. Ogorelkova
et al. described a G to A substitution at the +1 donor splice site of the apo(a) KIV-8
intron that results in alternative splicing of the intron and thus encodes a truncated
apo(a) form [40]. The shorter apo(a) form is missing the KIV-9 domain (as well as
KIV-10, KV and the protease domain) which is essential to form a stable covalent
Lp(a) complex. The authors concluded from their genotyping results in a Tyrolean
(n=113) and a Finn (n=126) population that approximately 11% of the Europeans
are heterozygous and 0.3% are homozygous for the G to A splice site mutation; the
one homozygous individual had an extremely low Lp(a) level (0.03 mg/dl) [40]. In
the present investigation of 2,491 individuals only one homozygous individual was
found (=0.04%), with this individual having a Lp(a) level of 7.4 mg/dl. 5.6% of the
individuals were heterozygous and had a lower (mean Lp(a) 15.6 mg/dl) Lp(a) level
than individuals homozygous for the frequent allele (mean Lp(a) 32.2 mg/dl). While
an association of the minor A allele with lower Lp(a) levels could be confirmed, this
mutation can not explain the variability of Lp(a) levels on the population level, due
to its very low allele frequency.
For the +79170 G>A SNP, but not for any other SNP analyzed, a strong associ-
ation (P< 0.001) in all populations with the presence of only one detectable apo(a)
isoform size in serum was found. The KIV-2 repeat polymorphism was not geno-
typed but the apo(a) isoform size in serum was measured. The number of expressed
KIV-2 repeats was estimated with a standard [52]. In the present study 48% of the
persons analyzed had only one detectable apo(a) isoform size. The mean Lp(a) level
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of individuals with only one expressed isoform of 29.2 mg/dl is significantly lower
than the mean Lp(a) of 33.5 mg/dl for individuals with two different sized apo(a)
isoforms, but the distribution of KIV-2 repeat number ranged randomly from 2 to
45 repeats in both groups. In the group of individuals where only apo(a) isoform
of one size could be detected the bigger part is due the expression of only one LPA
allele. However, this group includes homozygotes for the same number of alleles,
as well as individuals with one very large isoform, where concentration is low and
blotting of this large molecules is often incomplete and thus detection difficult. But
again this very rare SNP (minor allele frequency 2.8%) can only explain a small
proportion of these “not expressed alleles”. The +79170 G>A SNP was investi-
gated to exclude an influenc of this SNP on the effects seen for rs11751605 on the
Lp(a) level. The influence of rs11751605 on the Lp(a) level for the different +79170
G>A SNP genotypes was analyzed in all populations and higher Lp(a) levels were
found for rs11751605 CC/CT allele carriers independent from the +79170 G>A SNP
genotype. This effect reached significance only in the +79170 G homozygous as the
number of heterozygous individuals was small.
The other investigated rare SNP marker rs3798220, was identified in a search
for genetic variants associated with severe coronary artery disease in a population
of Americans with European descent [93]. The variant was identified from 12,077
putative functional SNPs in more than 7,000 genes in a three stage design (with 1,806
cases and 1,274 controls in total) and was the only investigated SNP marker that
showed significant association with severe CAD in that study [93]. The alleles of the
SNP marker rs3798220 were given by Luke at al. as A>G [93]. They detected a MAF
of 5.2% in the (third) case sample and a MAF of 2.7% in the (third) control sample
[93]. These allele frequencies are well comparable to the MAF determined in the
present investigation, though nomenclature differed. Here, the alleles of rs3798220
are given according to dbSNP as T>C. For the both samples from the MI family
study (Index MI patients and affected CAD siblings) a MAF (for the C allele) of
6.6% was detected. The MONICA control sample showed a MAF of 2.6% and a
nearly identical MAF of 2.5% was found in the KORA MI cases sample. According
to the similar MAFs, also the obtained odds ratios were comparable. Luke at al.
observed an odds ratio for severe CAD of 3.14 (95% CI 1.51 to 6.56, P=0.005)
for carriers of the minor allele after adjusting for traditional risk factors (age, sex,
smoking, hypertension, diabetes, dyslipidemia and BMI) [93]. In the family samples
an adjusted odds ratio of 2.26 (95% CI 1.21 to 4.23 and P=0.01) was obtained
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for CAD, and an odds ratio of 2.74 (95% CI, 1.54 to 4.98, P=0.0007) for MI was
obtained for carriers of the minor allele when compared to MONICA controls. In
contrast to these findings, no association of rs3798220 could be detected in the
sample of incidental KORA MI cases, when compared to the control sample. No
obvious reasons (e.g. bad genotyping performance) can explain this non-replication
in the KORA sample.
Therefore, no consistent replication of the association of rs3798220 with MI/CAD
could be shown in the present investigation.
Luke et al. investigated also association of rs3798220 with plasma Lp(a) levels
in 646 subjects and found significantly higher Lp(a) levels (P=0.003) in carriers
of the minor allele [93]. Furthermore, they demonstrated in a sub-sample of these
subjects (n=122) that this effect was not due to apo(a) size differences, as the
association with Lp(a) levels (P=0.002, median Lp(a) level 5.9 fold higher for rare
allele carriers) remained significant (P=0.01, median Lp(a) level 3.7 fold higher for
rare allele carriers) after adjustment for apo(a) size [93].
In the present investigation, the association of rs3798220 with Lp(a) levels could be
confirmed in all MI/CAD samples and in the general population sample (MONICA
controls). The effect of rs3798220 on Lp(a) levels was well comparable to the effect
size reported by Luke et al. In the present investigation, carriers of the minor allele
had in all populations about 8 fold higher median Lp(a) levels than non-carriers.
However, as in the case of +79170 G>A, rs3798220 can not explain the variability
of Lp(a) levels on the population level, due to its low allele frequency.
A mechanism for the influence of rs3798220 on Lp(a) levels and CAD could not
be shown so far. However, Luke et al. proposed a possible mechanism for the
influence of rs3798220 on Lp(a) levels and CAD risk. From the location of the SNP
rs3798220 in the protease domain of LPA, and the putative resulting amino acid
change from isoleucine (I) to methionine (M), Luke et al. proposed a possible role
of this amino acid change on Lp(a) catabolism and oxidation status [93]. They
speculated that the oxidation of this methionine residue could alter the properties
of apo(a) and Lp(a), in analogue to apolipoprotein A-I, where it has been shown
that the oxidation of methionine residues can alter sites and rates of the proteolytic
cleavage of apolipoprotein A-I [93].
Taken together, the finding that two neighboring SNPs, rs11751605 (located in
intron 34) and rs3798220 (located in exon 36), show association with Lp(a) levels
and with MI/CAD, give further hints that mutations in the protease domain of the
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LPA gene could have a strong influence on the catabolism of Lp(a), as well as on its
atherogenic properties.
4.1.2 Possible influences of rs11751605 on functional
properties of Lp(a)
The mechanism by which rs11751605 influences Lp(a) concentrations, thereby act-
ing detrimental on the process of atherosclerosis, remains speculative. A direct
causative effect of the SNP appears unlikely due to its genomic location in intron
34 (figure 3.1). Potentially, the marker rs11751605 tags another functional muta-
tion in one of the neighboring domains of KV domain (encoded by exons 32 and
33) or the serin protease domain (encoded by exons 34 to 39) that alters the prop-
erties of the apo(a) molecule. An influence on the receptor binding properties of
the molecule might be conceivable, thus increasing the levels of circulating Lp(a)
particles. Lp(a) is degraded in vivo by elastases, dividing apo(a) in two parts, with
the C-terminal domain spanning from KIV-5 to the protease domain [26]. Recent
studies in transgenic mice indicate that this C-terminal apo(a) component mediates
Lp(a) clearance from plasma by the liver [34]. The apo(a) clearance has been shown
to be independent from LDL receptor or apoE and is supposed to run via a receptor
that is responsible for the hepatic clearance of cholesterol-rich remnant lipoproteins
(RLP) [34, 79]. Enhanced levels of RLP might further increase atherosclerosis [79].
Edelstein et al. found that lysine residues of the KV domain of apo(a) mediate
binding with oxidized phosphatidylcholine and postulated that apo(a) might act as
a scavenger and prevent LDL from oxidation [13]. Recent findings by Tsimikas et al.
showed that Lp(a) levels strongly correlate with the oxidized phospholipid/apoB-100
ratio in plasma and that both factors are associated with the extend of angiographi-
cally documented coronary artery disease [42]. In conjunction with the finding that
the oxidized phospholipids are physically associated with Lp(a) via the KV domain
of apo(a)[13], this supports the idea that in a setting of enhanced oxidative stress
the atherogenic properties of Lp(a) might be enhanced through pro-inflammatory
oxidized phospholipids. Prolonged circulation of Lp(a) due to delayed clearance in
a setting of enhanced oxidative stress might therefore strongly promote atheroscle-
rosis. SNP rs11751605 is located in the vicinity of the KV domain and linkage
disequilibrium with this functional site exists according to HapMap data.
On the other hand, alternative hypotheses to explain the detrimental properties of
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Lp(a) on atherosclerosis exist [121, 122, 37, 123]. Both, independent confirmation
of the association results and functional studies are certainly warranted.
A limitation of the present study is that the Lp(a) levels have not been measured
with an assay that is independent for size. However, this issue can considered less
relevant as the expressed apo(a) sizes were determined. Furthermore in the present
study the influence of polymorphisms of the promoter region of the LPA gene was
not considered. Promotor polymorphisms (for example the pentanucleotide repeat
(PNR) polymorphism) have been repeatedly associated with Lp(a) concentrations
[56, 87, 50]. For Caucasian populations the promoter polymorphisms have been
shown to be in strong LD with the KIV-2 polymorphism [50, 89, 28] and thus,
might themselves not contribute independently to the overall variation of Lp(a).
Furthermore it has to be stated that all SNP markers in the present investigation
were analyzed only in Caucasian populations and therefore the described associa-
tions with Lp(a) levels and MI/CAD are restricted to this ethnicity.
4.2 Genome-wide association data
The genome-wide association of SNP markers from the GeneChip Human Mapping
500K Array Set with Lp(a) levels in the present investigation, clearly proved the huge
influence of the LPA gene region on the Lp(a) levels. An association of SNP markers
within the LPA gene region with square-root transformed Lp(a) levels providing P
values of up to 2.4 E-10 could be shown. P values in this order of magnitude can be
considered as genome-wide significant, even when the threshold of 1.0 E-7 resulting
from the conservative Bonferroni approach is applied [124]. The Bonferroni approach
is widely used and accepted to address multiple testing in association studies. While
for an association analysis testing 5 SNP markers the Bonferroni approach changes
the initial level of significance of 0.05 to 0.01, the level of significance drops to 1.0
E-7 for the testing of 500,000 SNP markers [124]. The level of significance in GWA
studies has been matter of discussion, as the power to detect P values of 1.0 E-7
can be limited in studies with a small sample size [124]. Therefore a specific result
from a GWA study is more emphasized by consistent findings in several replication
studies that by the mere strength of the P value in the initial study [124]. A robust
replication strategy thereby also reduces the false positive results [124].
Quite disappointing, the GWA analysis could not enhance SNP coverage of the
LPA gene itself. Though the number of 500,000 SNP markers represented on the chip
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used for genotyping is astonishing, on gene levels the SNP coverage shows gaps and
a substantial proportion of the known SNPs are not captured [124]. This problem
is widely known and manufacturers have answered with the next generation chips,
providing information on nearly 1 million SNPs [124]. Furthermore the gaps in SNP
coverage are strongly embroidered when SNP markers have to be excluded from the
analysis due to a high missingness rate. The quality of the genotyping procedure
is the determining factor and the suboptimal call rates of 97.8% and 97.2% in the
present investigation as well as the low intensity cluster plots surely do not prove a
perfect quality of the genotyping procedure. It should be noted that in the present
investigation the data of a already performed GWA analysis were re-analyzed and
therefore, the quality of the genotyping procedure could not be influenced.
Though GWA analysis offers the possibility to identify genes previously unsus-
pected of being related to a phenotype or disease [124], in the present investigation
of factors influencing the Lp(a) levels a different strategy could be more promising.
Linkage analysis has led to the initial finding of the locus on chromosome 6q27 as
the major determinant of Lp(a) levels. However, several other loci with significant
LOD scores were identified when the effect of the chromosome 6 locus was taken
into account [81, 82].
An investigation of the genome-wide SNP data in a region of chromosome 1 that
had previously shown linkage with Lp(a) levels [81] failed to give clear evidence of a
second “hot spot” of SNP markers associated with Lp(a) levels. Also an adjustment
for the highly significant associated SNPs in the LPA gene region did not improve
the association signals for the chromosome 1 region. In part these findings may be
explained by gaps in the SNP coverage. A recent investigation by Barlera et al.
investigated linkage of Lp(a) in a large sample of 4,012 individuals from 1,812 fam-
ilies. The sample was comprised of European CAD patients and families collected
through the PROCARDIS coronary heart disease study [82]. They identified several
loci with significant (chromosome 13q22-31 and 11p15) and tentative (chromosome
15q23-25 and 19q13.4) linkage, after the effect of the chromosome 6 locus had been
considered [82]. This study also could show linkage for the locus on chromosome
1q23 (previously identified by Broeckel et al.), but with a not significant LOD score
of 1.5 [82].
Though the first attempt to identify SNP markers associated with Lp(a) levels
from the GWA analysis in regions of linkage has failed, the idea of narrowing the
huge genomic regions underlying QTL regions with the use of genome-wide SNP
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data to identify appropriate candidate genes may still be promising and should be
applied in the future work on identification of modulators of Lp(a) levels.
An other aspect that could be considered in the search for modulators of the Lp(a)
levels was recently provided by the findings of Becker et al. [77]. They reported the
existence of a extracellular Lp(a) oxidase that catalyzes the covalent Lp(a) assembly
[77]. Variances of this Lp(a) oxidase may have a profound influence on Lp(a) levels.
Therefore, a screening for genes harboring a oxidase motif in the regions of linkage
or association might be an alternative strategy.
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5 Summary
Elevated serum Lp(a) levels are a risk factor for atherosclerosis and myocardial in-
farction. Lp(a) serum levels are highly heritable, and to a great extend determined
by the LPA locus on chromosome 6q27. Polymorphisms influencing the Lp(a) lev-
els have already been identified, but a proportion of the variance in Lp(a) levels
remains to be explained. In this investigation different methods were used to ex-
plore the influence of SNP markers located in the LPA gene region on Lp(a) levels.
The methods comprised a pooling strategy that made use of data from a previous
linkage analysis, and served as a screening tool for probably relevant SNP markers.
For several SNP markers an association with serum Lp(a) levels could be shown.
The identified SNP markers were genotyped in individuals of a large family sample
and findings were replicated for all investigated markers. In a third step, a sample
of the general population was investigated to underline the robustness of findings.
Furthermore, for SNP markers showning a strong association with Lp(a) levels, the
association with MI/CAD was investigated. Particularly one SNP marker in the
LPA gene could be identified. This marker (rs11751605) showed a strong influence
on Lp(a) levels in multiple populations and is significantly associated with both
familial and incidental MI. Moreover, it contributes to the evidence of linkage to
the Lp(a) locus on chromosome 6q27. Association with Lp(a) levels and with CAD
could be replicated for a SNP marker (rs3798220) recently described in the litera-
ture. Furthermore data from a genome-wide association analysis using 500,000 SNP
markers were analyzed. The results provide the basis for the identification of factors
(apart from markers in LPA gene region) modulating Lp(a) levels.
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